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Resumo
O cancro da tiroide é tipo de neoplasia endócrina mais frequente, estando na maioria das vezes
associado a um excelente prognóstico que deve à terapia com iodo radioativo.
Como a única função do iodo no organismo humano está relacionada com a síntese de hor-
monas tiroideias que ocorre na própria glândula tiroideia, este radionuclídeo apresenta uma ele-
vada especificidade para a glândula em questão. Além disto, 80% dos casos são do tipo papilar,
que possuem a capacidade de reter as funções biológicas básicas características do tecido glandular
normal, como por exemplo, a capacidade de captar iodo da circulação sanguínea.
Apesar da eficácia do tratamento, grandes quantidades de energia são emitidas durante o decai-
mento do iodo radioativo (131I), sob a forma de partículas e radiação eletromagnética, que possuem
diferentes capacidades ionizantes e de penetração. Desta forma, a terapia com iodo radioativo está
sujeita a regras estabelecidas pela legislação nacional, que visam minimizar a exposição à radiação
dos pacientes, familiares, membros do público e trabalhadores do serviço.
Muito resumidamente, os fatores de segurança dependem do tempo de exposição, da distância
à fonte radioativa e da blindagem. O objetivo deste trabalho é caracterizar e reprojetar um plano
de barreiras de um quarto já existente, de forma a torná-lo apto para a administração desta terapia,
tendo em conta os fatores de segurança supramencionados.
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Abstract
Thyroid carcinoma is the most frequent endocrine malignancy worldwide. The excellent prognosis
in an overwhelming number of cases is related to radioiodine therapy.
As the only function of iodine in the human body is the synthesis of thyroid hormones, within
the thyroid gland, this radionuclide presents high specificity for this gland. Moreover, 80% of the
incident cancers are papillary thyroid cancer (PTC) type, meaning that basic biologic characteris-
tics of thyroid normal tissue are retained, such as iodine uptake from the circulating blood.
Despite the efficacy of the referred treatment, large amounts of energy are emitted during ra-
dioiodine (131I) decay, in the form of particles and electromagnetic radiation with distinct ionising
and penetrating powers. Therefore, the administration of 131I within a nuclear medicine service
must follow strict rules determined by national legislation, in order to minimise the exposure to
radiation of patients, families, members of the public and workers of the facilities.
Briefly, the safety factors are related to the exposure time, distance to the radiation source and
the shielding barriers. The aim of this project is therefore to characterise and redesign a shielding
plan of a unit designated for the administration of 131I, taking in consideration these safety factors.
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Chapter 1
Introduction
The only function of iodine in the human body is related to the synthesis of thyroid hormones that
occurs within the thyroid tissue. As the chemical properties of radioiodine (131I) are similar to the
stable iodine’s properties [1], thyroid cells, normal or carcinogenic, cannot distinguish between
the unstable and the stable form of iodine. Therefore, this radioisotope presents high specificity to
this gland and for this reason thyroid carcinoma treatment with radioactive iodine (RAI) is highly
effective and popular nowadays.
Following 131I decay both β -particles and γ-rays are emitted. The first represent the highest
contribution to the success of the treatment, however the majority of the second ones, leave the
patient via the skin surface. As a result, the patient becomes a source of radiation, which definition
and undesirable consequences are explained below.
Radioactivity or radioactive decay refers to the stabilisation process of a parent nucleus into a
more stable daughter nucleus accompanied by energy emission [2]. This energy is called radiation.
An atomic nucleus is characterised by the number of protons (or atomic number, Z) and by
the number of neutrons (N) [2], the sum of which gives the atomic mass number. When there
is no optimal equilibrium between protons and neutrons, the nucleus is said to be unstable or
radioactive. When a radioactive substance contains atoms of same structure it is often referred
to as radioactive nuclide. These radioactive species decay until a more stable configuration is
achieved. Sometimes, this configuration is still unstable, resulting in a decay chain as far as a
stable nuclide is formed [3]. The decay rate or activity (A) of a radioactive nucleus represents the
total number of decays (or disintegrations) per unit time, therefore it may be expressed as
A =
dN
dT
, (1.1)
where dN is the expected number of nuclear transitions from a particular energy state in a certain
time interval dT . The SI unit of activity is the Becquerel (Bq), given as 1 Bq = 1 s−1 (one
Becquerel is equivalent to one nuclear transition per second) [4].
The activity of a radioactive substance at a certain time (t) is given by an exponential law,
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known as the fundamental decay equation or decay law:
A(t) = A(0)e−λ t , (1.2)
where A(0) represents the initial activity (at time t = 0) and λ corresponds to the radioactive decay
constant, a characteristic parameter for each radioactive decay process. This is the most important
defining characteristic of radioactive nuclides [3]. The time at which the number of radioactive
nuclei of the substance has already decayed to half of the initial value (given by dN in Equation
1.1) is called half-life, (t1/2). The relationship between this quantity and the decay constant, λ , is
given by the following equation:
λ =
ln2
t1/2
. (1.3)
The spontaneous radioactive decay processes are divided into three main categories. Each
process is accompanied by emission of energetic particles, as can be seen in Table 1.1. The type
of radioactive decay depends upon the nuclide involved.
Table 1.1: Particles emitted in the different natural radioactive decay processes (adapted from [3]).
Radioactive decay process Particle emitted
α decay α particles
β− Electrons, antineutrinos
β decay β+ Positrons, neutrinos
Electron capture Neutrinos
γ decay γ decay γ rays (photons)
Internal conversion Atomic orbital electrons
Therefore, the decay energy is emitted either as electromagnetic radiation or in the particu-
late form, by particles. Nevertheless, both present wave-particle duality, meaning that they can
be characterised as waves, by its amplitude, wavelength (λ ) and momentum (p) that are related
according to
λ =
h
p
, (1.4)
where h is the Planck’s constant (h = 6,626 × 10 −34J s). A quantum of electromagnetic radiation
is called a photon, which carries energy given by hν , where ν is the frequency given by v = c/λ ,
where c is the speed of light in vacuum (c≈ 3 × 108 m s−1). The energy per photon is expressed
in electron volts (eV).
The 131I decays by β− emission to excited states of the daughter nuclei 131Xe which decay
to the fundamental state by several γ emissions (as shown in the decay scheme in Appendix A,
Figure A.1). The first occurs when a nucleus has an excess of neutrons and attempts to reach
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stability by converting a neutron into a proton with the emission of an electron [2]. This often
results in an excited daughter nucleus that instantaneously (within 10−12 s) continues the decay
process to its ground state emitting the excitation energy in the form of gamma ray photons [3].
When an incident beam strikes a target, its particles can interact with the target nuclei and
orbital electrons by scattering, absorption and nuclear reaction. When crossing matter, the beam is
attenuated in intensity (I), energy (E) or both [3]. Hereupon, radiation can be classified, as shown
in Figure 1.1, as non-ionising radiation (NIR) and ionising radiation (IR). NIR cannot ionise
matter because its energy is not enough to disrupt chemical bonds and remove an electron from an
atom [2], while IR carries sufficient energy to remove bounds from atomic shells, thus producing
ionised atoms and molecules [2]. Therefore, one can say that IR energy exceeds the ionisation
potential of matter [3]. This threshold energy depends on the matter’s characteristics [2].
IR can ionise matter directly or indirectly. Directly ionising radiation consists of charged par-
ticles that through direct Coulomb interaction deposit energy in the medium. In its turn, indirectly
ionising radiation comprises neutral particles that deposit energy in the medium by release of a
charged particle which interacts with the medium as directly IR [3].
Figure 1.1: Classification of radiation (adapted from [3]).
In addition to the ionising ability, radiation is also able to penetrate through matter. The
penetrating power is inversely proportional to the ionising power, since radiation continues to
penetrate matter until it has lost all of its energy. Briefly, β particles have lower penetrating power
than γ rays, but higher ionising power. The reason is because β particles are charged, while γ rays
are electrically neutral and massless presenting relatively little interaction with matter. While for
beta particles the ionisation is more localised, for gamma radiation it is more spread out, since
they are not slowed by collisions.
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The penetrating power of radiation is reflected in the distance that they can travel through air.
β particles have a range in air of a few meters, while γ radiation can travel many meters, due to
little absorption or scattering as they pass through air [5].
Both directly and indirectly IR are used for disease’s diagnosis and treatment, in a branch of
medicine called nuclear medicine. Thus, radioactive isotopes are injected or ingested by the pa-
tient, and it is expected that calculated doses of ionising radiation emitted during decay of these
pharmaceuticals interact with metabolic or physiologic paths of the organism originating informa-
tive images or treating the disease, most often cancerous tumours. Concerning therapy purposes,
radiopharmaceuticals are designed to locate with high specificity the cancerous foci, even when
the location is unknown or it has already metastasised, while minimally damaging normal tissue.
This behaviour depends on the chemical and physical characteristics of the isotope.
Hereupon, the radiation emitted by radioiodine that is necessary for the success of the treat-
ment may also present a great extent of harm to all the other people around the patient. For this
reason, during the radioactive treatment, the patient should be isolated within a designated unit that
should follow radiation safety principles so that in the vicinity of this premises the radiation ex-
posure values are below those established by national legislation. These measures aim to provide
safety for other patients, families, members of the public and workers of the facilities.
1.1 Goals
The present work intended to redesign a shielding project for a specific room from Hospital CUF
Porto’s inpatient unit. The project was developed in strict collaboration with specialists from the
Medical Physics Department of Dr. Campos Costa. Both entities belong to the same group, José
de Mello Saúde.
The aforementioned unit was first conceived to accommodate an iodine therapy room, in par-
ticular, the highly effective thyroid carcinoma treatment, which consists in the ingestion of a spe-
cific dose of radioiodine by a patient, previously submitted to a thyroid gland removal surgery.
However, proper license was not provided and the room continued to be occupied with non-ra-
dioactive treatments’ patients. Currently, the Hospital CUF Porto’s board is dedicated to provide
this treatment to the community and, for this reason the room’s characteristics should be properly
reassessed in order to fulfil all the radioprotection requirements.
In order to propose an efficient shielding design for the facility in question, the work planning
was essentially divided in three parts:
1. Assessment of the radiation sources properties;
2. Exhaustive characterisation of the existing unit construction materials;
3. Determination of the exact characteristics of the necessary reinforcement to effectively at-
tenuate the radiation emitted during decay of the administered 131I radiopharmaceutical to
values accepted by Portuguese and European legislation.
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1.2 Report Layout
This thesis is organised in seven chapters.
Chapter 1 presents a few introductory concepts necessary to the comprehension of the scope
of this project. Motivation and goals of the present work are highlighted in this section, as well.
Chapter 2 presents detailed information concerning: the thyroid gland and the thyroid carci-
noma (Section 2.1), where physiologic aspects concerning iodine uptake in healthy and cancerous
thyroid tissue are pointed out; the 131I and the therapy with the radioisotope (Section 2.2), ex-
plained how the radiation emitted during radioiodine decay destroys malignant thyroid cells. This
chapter gives an insight relatively to the biomedical context of this radiotherapy and the reason for
its efficiency and popularity and why there is a need for a reliable shielding plan concerning the
energies and radiations involved.
Chapter 3 explains the processes by how radiation interacts with matter (Section 3.1), the bio-
logical tissue and the resulting biological effects (Section 3.3); how to characterise a radiation field
(Section 3.2); how to minimise radiation exposure values towards the regulatory recommendations
of radioprotection (Section 3.5 and 3.4); and how to efficiently shield a unit in a nuclear medicine
service where a patient submitted to 131I therapy will be isolated (Section 3.6). This chapter helps
to understand the need identified in the second chapter.
Chapter 4 presents the first part of the work performed which consists in the assessment of the
used radiation source properties that support the posterior experiments.
Chapter 5 characterises the unit structure materials, in the presence of different radioactive
sources with different range of energy emission.
Chapter 6 proposes a shielding plan as the solution to the identified problem.
Chapter 7 shows the conclusions and possible future work developments concerning shield-
optimisation aspects.
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Chapter 2
Biomedical Insight
2.1 Thyroid and Thyroid Carcinoma
Thyroid carcinoma is the most frequent endocrine malignancy worldwide, present in 5% of all
detected thyroid nodules, which occur annually in 20–50% of the general population [6]. The age
group peak incidence is 65–69 years in men and 45–49 years in women.
In Europe, there were 3,4 million new cases of cancer in 2012, but only 52 937 of which
corresponded to thyroid cancer type. Just 6 334 cases were related to death, which can be translated
in a mortality of 12% concerning incidence of thyroid cancer, and of 0,2% concerning total cancer
incidence. In women, thyroid cancer incidence was higher (40 654 versus 12 283 new cases in
men) [7]. In Portugal, the same trend was verified. In the same year, it was registered 576 new
cases (449 in women and 127 in men), associated with a mortality of 16% [8]. Hereupon, the
rarity of this malignancy, along with its excellent prognosis in an overwhelming number of cases,
are two of the main features of thyroid carcinoma [9].
As implied from the aforementioned statistical data, thyroid carcinoma is actually one of the
most common cancer in women [8], but despite the global higher incidence, there is no generally
accepted reason that may explain this sexual disparity. Thyroid cancer incidence also varies with
geographic area and ethnicity, which might be justified by genetic factors, environmental influen-
ces and access to medical care [10].
As it has been observed in recent decades, increasing incidence of thyroid carcinoma is ex-
pected [11, 12, 10], as shown in Figure 2.1. This increase may be due to the more sensitive
diagnostic procedures that allow the detection of small cancers in the preclinical stage. However,
a true increase is also plausible, as a consequence of increased population exposure to radiation,
environmental carcinogens due to the industrialised lifestyle and other still unrecognised carcino-
gens [10].
These considerations dictate the need for applying the more effective, less invasive and less
expensive approach able to guarantee the best quality of life for a disease that requires a follow-up
care throughout life, despite the intrinsic low mortality.
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Figure 2.1: Trend in thyroid cancer incidence in the North American population from 1980 to
2008 by histotype (adapted from [11]).
2.1.1 The Thyroid Gland
The thyroid gland is the largest endocrine gland, weighing about 15–20 grams in the normal
adult [13, 14].
It synthesises, stores and secretes two major hormones, required for the normal function of a
variety of physiologic processes affecting nearly every organ system in the body, as metabolism,
heart rate, body temperature and tissue growth. Thyroid hormones are essential for normal growth
and development and are most obvious during infancy and early childhood [15].
The thyroid gland acts as an important store of iodine in the human body, from which synthesis
of triiodothyronine (or T3, indicating 3 iodine atoms) and thyroxine or tetraiodothyronine (or T4,
indicating 4 iodine atoms) depend. The former is more abundant, but T3 is the most potent,
constituting 90% and 10% of thyroid secretion, respectively [14]. Hormone secretion is regulated
by the hypothalamic-pituitary-thyroid (HPT) system [13].
Thyroid dysfunction ranges from the overproduction or underproduction of thyroid hormones,
to the development of neoplasia. The possible diseases include hyperthyroidism, hypothyroidism,
Grave’s disease, Hashimoto’s thyroiditis, goiter, adenoma (benign growths of the thyroid) and
thyroid carcinoma.
2.1.1.1 Anatomy
The thyroid gland is located in the neck, inferior to the larynx and cricoid cartilage. It is formed
by two lobes, each about 5 centimetres long that are joined anteriorly by a narrow isthmus, over
the second and third tracheal cartilages. The lobes lay either side of the trachea and the oeso-
phagus [16]. In the posterior region of each lobe, four parathyroid glands are located. These are
responsible for the production of the parathyroid hormone [16].
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The thyroid gland is surrounded by a fibrous capsule that firmly connects the thyroid gland to
the larynx. This explains why the thyroid moves on swallowing. A schematic representation of
the thyroid gland anatomic position might be seen in Figure 2.2.
Figure 2.2: The thyroid gland (adapted from [14]).
The lobes contain about one million spherical structures called follicles, which represent the
functional units of the thyroid gland (Figure 2.3). Each follicle is lined by a single layer of cells
(secretory epithelial cells) around a colloid filled space. The follicular cells secrete the thyroglo-
bulin (Tg) glycoprotein into the lumen of the follicle. Thyroid hormones are synthesised at the
cell-colloid and must be bound up as residues of the Tg molecule during synthesis in order to
restrict their movements, due to their lipophilicity. In this sense, Tg in the colloid acts as precursor
and storage form of T3 and T4. When thyroid is actively secreting hormones, the colloid store
shrinks[14].
In between follicles, parafollicular cells (C cells) are also found. These are responsible for the
synthesis and secretion of calcitonin, involved in calcium homeostasis.
The thyroid is highly vascular, and consequently its appearance is more reddish than the nearby
tissue [14]. It is supplied about 5 millilitres of blood per gram of thyroid tissue, by three main
arteries (superior thyroid artery, inferior thyroid artery and thyroidea ima artery in just 10% of
people.) [16, 15]. It is drain by three veins (superior thyroid vein, middle thyroid vein and inferior
thyroid vein). The first two veins drain into the internal jugular, whereas the inferior vein drains
into the brachiocephalic veins.
2.1.1.2 Hormone Synthesis and Secretion
As a part of the endocrine system, thyroid main function is to regulate hormones in the body,
but unlike other endocrine glands, which secrete their hormones the moment they are produced,
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Figure 2.3: Follicular structure of the thyroid gland (adapted from [17]).
the thyroid gland stores considerable amounts of the thyroid hormones (T3 and T4) until they are
needed by the body.
Thyroid hormone synthesis is a step-by-step complex process that takes place in both colloid
and follicular cells. It depends on the presence of both tyrosine and iodine. Tyrosine, a non-es-
sential aminoacid, is the major substrate that combines with iodine to form thyroid hormones.
Tyrosine is converted in the interior of follicular cells into Tg glycoprotein, which contains ap-
proximately 110 tyrosine residues, in a process called Thyroglobulin synthesis. Unlike tyrosine,
iodine concentration in the plasma is very low, so it must be provided to the body. The primarily
supply is through diet (mostly dairy products and cereals), although it might be also absorbed from
the skin and lungs. Seawater is also a major source of iodine, that is the reason why coastal zones
tend to be the most iodine-enriched environments [18]. About 150 milligram of iodine is needed
per day [18] in order to prevent irregularities, but only a fraction of this is actually absorbed by
the thyroid gland cells. These are the only cells that can actively absorb plasma iodine and utilise
it in the synthesis of thyroid hormones. In fact, the only role of iodine in the body is related to the
synthesis of thyroid hormones and this is the main reason why the treatment of thyroid carcinoma
with radioiodine is highly thyroid tissue specific, and consequently, efficient.
The initial step in the formation of thyroid hormones is the absorption and concentration of
the iodide anion (I-). Normally, 30% of iodine uptake is translocated to the thyroid and 70%
directly excreted in the urine [15, 19]. In a process called iodine trapping, the thyroid follicle
actively pumps plasma iodide ions, through the specialised Na/I cotransporter (NIS), against a
concentration gradient from the extracellular fluid to the interior of the follicular cell, where it is
oxidised into iodine (I) by iodide peroxidase enzyme [17]. This increases the iodine concentration
in the thyroid gland by 30 times its concentration in the blood. During active stimulation, the
concentration of iodine can be as high as 250 times.
Once formed, iodine rapidly attaches to tyrosine molecules within Tg (Iodination of thyroglo-
bulin or Organification of iodide), resulting in monoiodotyrosine (MIT or T1) and diiodotyrosine
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(DIT or T2). Then, in a process called coupling, iodotyrosines are coupled together to form
iodothyronines. Two DIT molecules are coupled to form T4 (Figure 2.4) and one DIT and one
MIT are joined to form T3 (Figure 2.5). Only 20% of iodinated tyrosine undergoes coupling, with
the rest remaining as MIT and DIT.
Figure 2.4: Molecular structure of thy-
roid hormone T4 (3,5,3’,5’-tetraiodo-L-thy-
ronine) (adapted from [17]).
Figure 2.5: Molecular structure of thy-
roid hormone T3 (3,5,3’-triiodo-L-thyro-
nine) (adapted from [17]).
At this point, thyroid hormones are stored in the follicles until they are split off from Tg
and secreted into the bloodstream, under direction of thyroid-stimulating hormone (TSH or thy-
rotrophin). The secreted ratio of T4:T3 is usually 9:1, but because T3 is more active, 40% of T4
is converted into T3 at cells level [14].
Iodine is mainly excreted by the kidneys, after breakdown of the thyroid hormones.
2.1.1.3 Physiology
Thyroid is regulated by the TSH hormone, produced by the hypophysis, which in its turn is stimu-
lated by TRH (thyrotropin-releasing hormone) fabricated in hypothalamus. The blood concentra-
tion of thyroid hormones also influences TSH production.
TSH influences the synthesis of hormones in the thyroid, which are stored within the follicles.
70% of these hormones enter the circulatory system attached to thyroxine-binding globulin (TBG)
and the rest bound to other plasmatic proteins. The half-life of T3 and T4 is greatly augmented
from this bound, resulting in a immense reservoir of circulating thyroid hormones [14].
Once inside the cell, thyroid hormones interact with cell DNA to influence regulatory genes
and start the synthesis of new proteins. The newly formed proteins will mediate the cell response
to thyroid hormones. Although thyroid hormones affect virtually every tissue in the body, not all
have the same reaction. In most tissues the principal effect is related to metabolism, in other to
growth and maturation [14, 15].
2.1.2 Pathophysiology
The thyroid gland is prone to a number of diseases that can alter its function and structure. These
diseases may have wide-ranging systemic effects because, as previously said, thyroid hormones
regulate the metabolism of almost every cell in the body.
Thyroid carcinoma represents the most common and prevalent of all endocrine malignancies.
It is effectively treated with radioiodine therapy which associated radiation safety factors represent
the focus of this work. For this reason, this disease will be described in detail below.
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There are four main types of thyroid neoplasia, and some other subtypes, depending on the
type of thyroid gland cells, mentioned in Section 2.1.1, from which they are developed. Papillary
and follicular thyroid cancers develop from the follicular cells and grow slowly, medullary thyroid
cancer develops in the C cells and anaplastic thyroid cancer develops from differentiated thyroid
cancer or from a benign tumour of the gland and grows rapidly.
The first two cancers are classified as differentiated thyroid cancer (DTC), which means that
the tumour tissue has the same microscopic appearance as normal tissue. Consequently, cancer
cells are able to retain basic biologic characteristics, including expression of NIS and TSH re-
ceptors [20, 21]. However, some alterations in the metabolism might be present, such as: decrease
in the iodine uptake and organification; shortening of effective half-life (Te) of iodine; and decrease
in Tg expression [20].
Papillary thyroid cancer (PTC, 80%) is the most common type of thyroid cancer. It is usually
found in only one lobe (only 10–20% of papillary thyroid cancers appear in both lobes). Follicular
thyroid cancer (FTC,10%) is less common than the first one and may occur in more advanced
ages than the first one [22]. Both type of cancers represent 90% of total thyroid cancers and
are very often curable, especially when found early in people under 45 years [23]. Hürthle cell
cancer (HCC, 3%), is a FCT subtype, and is often classified on its own because it has a distinct
histological appearance and it is often less responsive to standard therapy [12].
DTC is considered the least aggressive type of thyroid carcinoma and has, in general, an
excellent prognosis. On the whole, greater than 90% of patients are alive after 10 years of diagno-
sis [12].
MTC has very little similarity to normal thyroid tissue and can be controlled if diagnosed and
treated before it spreads to other body parts. MTC constitutes about 5% of thyroid cancers [12, 24].
Anaplastic thyroid cancer (ATC) accounts for just 2% of total thyroid cancers and repre-
sents the most aggressive tumour, most commonly found in patients from the 50–60 years age
group [24]. Pathologically, ATC is grossly tan-white, fleshy, and large. During diagnosis areas of
necrosis and haemorrhage are evident. Cytologically, the tumour is characterised by high mitotic
activity and atypical appearing cells [25].
Between the period of 1980–2008, there have been registered an accentuated increase in the
incidence of the papillary histotype, with no significant change in the other three mentioned types
(Figure 2.1). The increase mainly regards small tumours, although the number of large tumours
has also registered a raise [10].
2.1.3 Current Diagnosis and Treatment Options
Diagnosis is important to access whether the cancer has metastasised and which treatment may be
the most effective. It may vary with patient age and medical condition, type of cancer suspected,
signs and symptoms and previous test results [22].
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In order to provide appropriate care based on current knowledge, there has been an attempt
to standardise care to enhance the treatment of thyroid carcinoma. General guidelines were es-
tablished, both in Europe [6] and Portugal [26], representing a consensus that ensure decreased
mortality and protection of patient’s quality of life, avoiding unnecessarily aggressive or ineffec-
tive treatments.
In Portugal [26], there was an attempt to identify prognostic factors that enabled the stratifi-
cation of patients into risk groups. Patient age, tumour size, extra-thyroid extension and presence
of metastases were consensually recognised. The most used prognostic scoring index is based in
TNM classification, which describes the extension of a person’s cancer by: T - tumour charac-
teristics, N - lymph node involvement, and M - distant metastatic lesions. This classification was
elaborated by Union Internationale Contre le Cancer (UICC) [27], and enables to assign cancer
cases to low-risk or high-risk, based on factors other than the anatomic extent of the disease. 80%
of the cases are considered low-risk patients [24].
A healthy thyroid gland is barely palpable. If a tumour develops in the thyroid, it might be felt
as a lump in the neck. Once the presence of nodules is confirmed, biopsy is performed in order
to classify a nodule as malignant or benign. As already stated, only 5% of all detected thyroid
nodules are malign [6].
The general primary approach for thyroid carcinoma is surgery, followed by radioactive iodine
(RAI) treatment and thyroid hormone suppression therapy [12]. The last one aims to keep TSH
levels low, since they are related to stimulation of thyroid growth.
Total thyroidectomy is the preferred surgery for high-risk DTC patients, while lobectomy (the
least invasive approach) is just considered for small (less than 1 centimetre) and isolated tumours.
Total thyroidectomy has low surgery associated complication (below 2%) [28, 24] and has been
shown to reduce recurrence rates of thyroid carcinoma [29]. This type of surgery is normally
followed by radioiodine therapy that will be thoroughly assessed in the next chapter. Briefly, a
remnant portion of thyroid tissue is often left after total thyroidectomy, so radioactive iodine (RAI)
can destroy any remaining thyroid cells, normal or malignant [12]. This procedure is associated to
better prognostics, especially in high-risk cases [30].
Treatment for MTC and ATC (tumours > 5 cm) is more controversial and might depend on
the cancer nature [24] and invasiveness [31].
2.2 131I Therapy
The use of radioactive iodine (RAI) for thyroid carcinoma treatment has changed over the past 50
years [20], based on increasing understanding of 131I biophysical properties and of iodine handling
by thyroid cells.
RAI treatment was reported for the first time by Seidlien et al.,1948 [32], in a patient whose
thyroid gland was completely removed but who was clinically hyperthyroid. This report confirmed
that metastatic thyroid cancer lesions could concentrate radioiodine.
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In the 1950s several groups began to evaluate the safety and efficacy associated with this
therapy [33, 34, 35] and by the 1960s this treatment was already associated with increasing survival
of thyroid cancer patients [36].
In the 1970s, 131I therapy became popular and more available commercially, as an increasing
number of studies [29, 37] were reporting good results in using 131I for thyroid remnant ablation
(RRA) to complete the surgical removal of all normal thyroid tissue and to destroy microscopic
deposits of thyroid cancer.
Nowadays, the use of 131I continues to represent a mainstay therapy for thyroid cancer due to
the efficacy of this treatment which is strongly related to tumour uptake and retention.
As explained in Section 2.1.1.2, thyroid follicular cells are the only cells in the human body
capable of concentrate iodide intracellularly, which is a prerequisite for radioiodine treatment, and
convert tyrosine into thyroglobulin (Tg) as a substrate for thyroid hormone synthesis. Thereby, the
surgical removal of all normal thyroid cells, gives the indication that the only remaining source of
Tg production is malignant thyroid cells, which makes serum Tg a more specific tumour marker.
In addition, any subsequent retention of radioiodine would be resultant of residual thyroid can-
cer [20]. Since radioiodine decays in a radioactive process, the energy emitted is responsible for
easily destroying the remnant malignant thyroid cells.
Data suggest that RAI decreases disease progression and mortality [38] in high-risk patients.
However, in low-risk patients the benefits of RAI are still uncertain, which requires the treatment to
be used selectively. In addition, the growing awareness of its short- and long-term consequences,
including damage to salivary glands, bone marrow, and gonads, especially when given in high
and cumulative doses and ineffectiveness when treating advanced metastatic thyroid carcinoma
demands for a more cautious and conservative approach [12]. The future role of RAI therapy
strongly depends on expanding knowledge of its relative risks and benefits which will be discussed
below.
2.2.1 Radioisotope
2.2.1.1 Production
Iodine-131 (131I) or radioiodine is an important radioisotope of iodine that can be produced on
large scales either from tellurium (Te) or from uranium (U).
Most 131I results from neutron-irradiation of a natural tellurium target. The heaviest isotope,
130Te, absorbs a neutron to become 131Te, which β -decays into 131I with a half-life of 25 min [39].
A tellurium compound can also be irradiated while bound as an oxide to an ion exchange column.
In order to obtain 131I, iodine can be separated from the tellurium targets by dry or wet distillation
followed by dissolution in an alkaline solution [40].
131I can, as well, result from nuclear fission of 235U resulting into fission fragments, 131I and
other iodine isotopes [2]. This technique requires elaborate equipment, purification and waste
handling procedures, and for this reason, it is the less employed [40].
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2.2.1.2 Physical and Chemical Characteristics
The chemical properties of radioiodine are similar to the stable iodine’s properties [1] so, con-
sequently, it is involved in the same metabolic and physiologic processes that were thoroughly
described in Section 2.1.1. This is one of the main reasons why thyroid cancer treatment with
radioiodine is so effective since thyroid cells, normal or carcinogenic, cannot distinguish between
the unstable and the stable form of iodine.
Radioiodine is highly volatile and soluble in water (0,034g/100ml at 25oC). Its melting point is
at 113oC and the boiling point at 184oC [41]. Thus, pure 131I is a black-violet coloured crystalline
solid at room temperature, but because it readily combines with other elements, radioiodine is
usually found as a compound rather than its pure form. When 131I is released into the atmosphere,
it often bounds chemically to hydrogen and oxygen or methane in gaseous form [42].
131I has 78 neutrons and 53 protons in its nucleus and a half-life (t1/2) of 8,0233 days [43].
During 131I decay, 90% of the radiation is delivered by β - particles (131I→ β−+ 131Xe?) and 10%
by γ emission (131Xe?→ γ+ 131Xe), transforming 131I into the stable 131Xe (Xenon).
The maximal energy emitted during β decay is 807 keV and the minimum energy is 248 keV,
but 89% is 606 keV. After emission of β - particles, the excited daughter nuclei (131Xe?) undergo
further adjustment with emission of γ-rays, between 80 and 723 keV, with 82% abundance of 364
keV [43]. The detailed decay scheme of radioiodine can be consulted in Appendix A, Figure A.1.
In the thyroid gland the biological half-life (Tb - amount of time required for the organism to
remove half of the initial administered dose via biological excretion pathways) of iodine is about
120 days [44, 43]. Consequently, the effective half-life (Te - period of time in which half of the
administered dose is removed by both normal excretion and radioactive decay) of radioiodine,
calculated from
Te =
t1/2 ·Tb
t1/2 +Tb
, (2.1)
is 7,52 days [45]. For other organs and tissues, it is assumed that organic iodine is retained with
a Tb of 12 days [46], which results in a Te of 4,81 days. Thus, two processes act to reduce the
total activity in the thyroid gland: physical decay of 131I represented by its physical half-life (t1/2)
and biological elimination, which depends on the metabolic activity of the cells, represented by
biological half-life (Tb).
The gland picks up iodine very rapidly and because γ radiation is highly penetrable, γ activity
in the gland can be detected a short time after a dose is administered. However, twenty-four hours
after administering of RAI, it already corresponds to 12 to 40% of initial dose [47]. The majority of
γ rays leave the patient via the skin surface, radiating the patient and the environment. Therefore,
the damaging effects to the cancer cells result mainly from the interaction of β particles with cells.
In fact, the harm is restricted to thyroid cells (Figure 2.6), due to the minimal penetration of β
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particles in soft tissue (approximately 1 mm) [48, 44]. For these electrons, LET is approximately
0,25 keV/µm [49]. As will be explained in Chapter 3, this damage affects the DNA chain and
either it is impossible to repair or the double strand is repaired incorrectly, leading to cell death
while trying to activate mitosis. Many healthy and malignant cells undergo radiation-induced
apoptosis [44].
Figure 2.6: Penetration of the particle β - in the thyroid tissue which is up to 1 mm (from [48]).
2.2.2 Procedure
131I administering should be preceded by a total thyroidectomy. 4–6 weeks after surgery, if a 131I
scintigraphy reveals residual tumour in the neck region or distant metastases, the patient is referred
to thyroid remnant ablation (RRA) [26].
RRA refers to the postsurgical administering of 131I , in order to destroy any residual thyroid
tissue, based on the assumptions that it may decrease the recurrence and the mortality rate [26, 29,
37] and facilitate the early detection of recurrence based on serum Tg measurement.
In normal conditions, thyroid cancer cells absorb from the blood only minor quantities of
radioactive iodine that would not be enough to destroy all the malignant cells. However, when
TSH is elevated, the iodine uptake capacity of these cells increase substantially [22]. For this
reason, a thoroughly preparation of the patient is needed, before addressing the patient to RRA.
Traditionally, preparation for RRA involves a low-iodine diet (<50 µg/day) and withholding
LT4 (levothyroxine) thyroxine replacement to increase endogenous TSH secretion, thereby stimu-
lating iodine uptake and release of serum Tg by thyroid cells. Usually, patients are referred for the
treatment when TSH concentration has risen to 25–30 µU/mL [20, 26]. It is believed that this TSH
level increases NIS expression thereby contributing to an optimisation in radioiodine uptake [50].
However, this procedure is usually associated to a state of hypothyroidism that may affect patient’s
quality of life.
As an alternative, recombinant human thyrotropin (rhTSH) might be used in order to trigger
the same effect, originating significantly fewer symptoms of hypothyroidism [51]. Side-effects are
associated with mild and transient nausea or headache [51].
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131I is available for oral ingestion (liquid solution or in capsules) as sodium iodine (NaI) of high
specific activity [44, 20], although it may also be administered intravenously in patients who are
unable to ingest the radioisotope. Capsules are safer than liquid solutions since less radioactivity
is released into the air during handling due to a reduction in volatility provided by the gelatin coat.
In addition, capsules also cause less oral mucosal irritation [20].
Apart from the thyroid gland, the normal biodistribution of iodine include salivary glands,
stomach, intestine and urinary tract, as can be seen in Figure 2.7, which means that these areas
receive relatively high doses during therapy. Even though 131I is rapidly absorbed, simultaneous
ingestion of large quantities of water attenuates the radiation dose that may be emitted to the
gastric and intestine walls during dissolution of the capsule. The major excretion pathway of 131I
Figure 2.7: Physiological uptake of 131I: anterior (ANT) and posterior (POST) views (from [44]).
is via urine. If a patient consumes 3–4 L/day of water, most of the radionuclide will be expelled in
the first 48 hours [52]. However, 131I may also be excreted by other means such as saliva, where it
may reside for 7 days.
The main side effect of 131I is the high incidence of early and late hypothyroidism [53], how-
ever occurrence of bone and soft tissue, colorectal and salivary gland cancers are also associated
to 131I exposure [54]. Administration of 131I is strictly contraindicated in pregnant women, since
cells in the process of division, such as the fetus, the bone marrow and the intestinal lining, are
more likely to be induced into apoptosis than cells in a quiescent state [55]. In next section,
radiation interaction with the biological tissue will be analysed in more detail. For cumulative
activities higher than 18,5 GBq (or 500 mCi), the risk of leukaemia is significantly increased [20].
Nonetheless, the most clinically evident side effects of treatment with 131I are usually minimal and
transient. Thus, the treatment conditions should optimise the radiation dose delivered to normal
and neoplastic thyroid tissues and minimise the radiation dose delivered to others in the vicinity of
the patient. The latter aspect represents the main focus of this work and will be assessed in detail
in the next Section.
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Chapter 3
Radiological Protection
Before addressing the radiation shielding topic in detail, it is important to understand the hazards
related to radiation emission, in particular during 131I decay, and why there is a huge concern in
blocking, or at least attenuating, its propagation.
Radiation safety is an essential topic associated with the treatment of thyroid carcinoma pa-
tients with 131I.
This chapter defines the main concepts that govern the radiation exposure and interaction with
matter.
3.1 Radiation Interaction With Matter
As already highlighted in Section 2.2.1.2, radioiodine decays by β− emission followed by γ de-
cays of the daughter nuclides. The β emission delivers the major radiation dose to the thyroid
tissue, whereas the γ emission may pose an external source of radiation exposure to individu-
als who come into close contact with the patient. When these particles strike a target, different
interactions may occur as explained below.
3.1.1 Charged Particle Interaction
Each charged particle is surrounded by its Coulomb electric force field, which interacts with the
atoms it encounters as it traverses matter. In each interaction, the energy transfer, from the charged
particle to matter, is generally small, which means that the particle undergoes a large number of
interactions before its kinetic energy is expended. This gradual loss of energy is described by the
stopping power, which depends on the charged particle’s (mass, charge, velocity and energy) and
on the absorber’s (density ρ and atomic number Z) characteristics.
When the interaction occurs with atomic electrons it is called collision loss, which causes
excitation and ionisation of the atoms; when it happens with the nucleus it is called radiative loss
and energy is transferred to photons by emission of bremsstrahlung, which only light charged
particles experience [3, 55].
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The charged particle’s path may be altered in each interaction (elastic or inelastic scattering),
behaviour that is more pronounced for light charged particles. Scattering refers to the deflection
of the particle from its original trajectory following an interaction. Elastic scattering occurs when
the total kinetic energy is unchanged, while inelastic implies loss of kinetic energy [2].
As a result of multiple scattering events with very large scattering angles, electrons follow
tortuous paths in matter [2, 3]. The biologic consequence of this non-uniform ionisation path can
be quantified by the linear energy transfer (LET), which is the amount of energy deposited in
matter by a charged particle as it travels through it (expressed in eV/cm) [2]. Radiations with low
LET, such as electrons and β− particles, are less dangerous to tissue [2].
3.1.2 Photon Interaction
When traversing an absorbing medium, photons experience numerous interactions with the atoms
of the medium that may involve their nucleus or the orbital electrons. The type and probability
of each interaction depend on the photon’s energy, hν , and on the absorber’s atomic number Z
and density ρ . Among all the known photon interactions, only four of these are of importance to
medical physics, and for this reason, will be given special emphasis in this report.
After each interaction, the photon may disappear (that is, completely absorbed) and its energy
transferred to light charged particles (electrons and positrons); or scattered. If the scattered photon
has the same energy as the incident photon, no light charged particle is released; if the resulting
scattered photon has lower energy than the incident one, then the energy excess is transferred to
a light charged particle [3]. In its turn, the light charged particle loses its energy following the
interactions mentioned before (see Section 3.1.1).
Photoelectric effect
This interaction occurs between a photon and a tightly bound orbital electron of the absorber
medium atom. A tightly bound electron is an electron whose binding energy EB is comparable to,
larger or slightly smaller than the photon energy hν [3].
In the photoelectric effect, the incident photon energy is completely transferred to the electron,
which is ejected from the atom with a kinetic energy EK = hν −EB [2]. Hence, the photon is
absorbed and the electron is now called a photoelectron. The vacancy in the shell is then filled
with a higher orbit electron. The difference in energy between the two transition states is emitted
either in the form of a characteristic (fluorescent) photon or in the form of an Auger electron [3].
The lower the photon energy and the higher the atomic number Z of the absorber, the more
favoured is the photoelectric effect [56].
Compton scattering
The incident photon interacts with an outer shell electron, resulting in electron ejection and
change in the trajectory of the photon with some reduction in energy.
The scattering angle θ (angle between the directions of the incident photon and the scattered
photon) can range from θ = 0◦ (forward scattering), through θ = 90◦ (side scattering) to θ = 180◦
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(back scattering). When θ = 0◦, the energy of the scattered photon equals the energy of the
incident photon, hence no energy is transferred to the electron. Therefore, it is a classical Thomson
scattering [3]. Thomson scattering is a photon-orbital electron interaction, where the electron is
a loosely bound electron. A loosely bound electron has a small binding energy EB in comparison
with photon energy hν . This results in an elastic scattering of the photon.
In Compton scattering, when low energy photons (hν < 10 MeV) interact, most of the energy
goes to the scattered photon instead of going to the recoil electron. This is the case of iodine γ-
ray photons, whose maximal energy is 723 keV. When high energy photons interact, the opposite
happens.
This interaction represents the predominant interaction of γ-ray photons with soft tissue [2].
Rayleigh scattering
In Rayleigh scattering, the incident photon, normally with low energy, interacts with the whole
atom of the absorber, usually with high Z. As result, a photon with exact same energy, but with
different direction, is emitted. The higher the Z, the higher the scattering angle θ . However, θ de-
creases with increasing photon energy, hν . As all the orbital electrons contribute to the scattering
event, it is referred as coherent scattering.
Because no electrons are ejected, following this interaction, ionisation does not occur [2].
Therefore, the atom is neither excited nor ionised and after the interaction, the bound atomic elec-
trons revert to their original state.
Pair production
Pair production occurs when a high energy photon interacts with the Coulomb field of an
atomic nucleus or orbital electron. As a result, the photon’s energy is transformed into an electron-
positron pair [3]. Hence, the photon is completely absorbed and its energy transformed into mass.
Pair production is followed by annihilation of the positron with an orbital electron of the
absorber.
The probability for pair production increases with the incident photon energy, especially in
higher Z materials [56].
3.1.3 X-ray Production
As charged particles and photons interact with matter, secondary X-rays production may occur.
There are two principal methods that are explained below.
Characteristic X-rays
When there are left vacancies in the lower shells, either by ionisation of inner electrons or
through excitation of electrons to higher energy levels, the electrons begin a series of transitions
until the ground state of the atom is achieved.
The discrete energy correspondent to the difference in the binding energy between the final
and initial states is either emitted as a photon, a characteristic X-ray, or ceded to an outer electron,
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which is ejected from the atom and for that it is called an Auger electron. Each electronic transi-
tion probability depends on the Z number of the atom and, thus, the characteristic X-rays provide
a unique signature for each element [55].
Bremsstrahlung
As previously said (see Section 3.1.1), charged particles stopping power can be of two types:
collision loss or radiative loss. In the last case, the photons produced are called bremsstrahlung
(literally “braking radiation”) [55].
Bremsstrahlung is more relevant for light charged particles with high energy in high-Z mate-
rial [3, 55].
3.2 Radiation Field
Radiation field refers to all the particles and their trajectories in some region of space or through
some boundary, either per unit time or accumulated over a certain period of time [55].
This section describes how to characterise a radiation field in terms of radiometric and dosi-
metric quantities, according to national legislation and Shultis et al., 2010 [55]. Radiometric quan-
tities are not enough related to most of the radiation effects to be a useful determinant. Therefore,
dosimetric quantities are used with the purpose of correlating a physical measure with a radiation
effect.
3.2.1 Radiometric Quantities
Fluence
In a radiation field, fluence Φ is defined as the number of particles, dN, penetrating into a
sphere of cross-sectional area, dA, as
Φ =
dN
dA
. (3.1)
Fluence rate
The fluence rate or flux is expressed in terms of the number of particles entering a sphere, per
unit time:
φ =
dΦ
dt
. (3.2)
3.2.2 Dosimetric Quantities
Absorbed dose
Absorbed dose (D) is defined as the absorbed energy per unit mass, in gray (Gy),
D =
dE
dm
, (3.3)
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where dE is the mean energy imparted to the matter by ionising radiation in a volume element
and dm is the matter mass in the volume element. This is a very useful concept in radiation pro-
tection, since energy imparted per unit mass in tissue is very closely correlated with radiation
hazard. However, D does not provide information about the total mass of tissue exposed and/or
distribution of the absorbed energy.
Equivalent dose
The equivalent dose (HT), in sievert (Sv), is the absorbed dose by the tissue or organ, weighed
by the radiation type R, according to,
HT = wRDT,R, (3.4)
where DT,R is the mean absorbed dose by the tissue or organ T and wR is the weighing factor con-
cerning to the radiation type. For photons (γ) and electrons (β−) emission, the radiation weighing
factor (wR) is 1, thus concerning 131I therapy, the equivalent dose (HT ) equals the absorbed dose
(D), in each tissue or organ T . In Appendix B, Table B.2 presents the weighing factors for other
radiation types, obtained from Directive L 013, OJEU, on 17th January 2014 [4].
When the radiation field is composed by different wR values, the total equivalent dose is given
by the summation of individual equivalent doses, HT.
Effective dose
The effective dose (ED), in sievert (Sv), is obtained from the summation of the equivalent
doses (HT) to each organ or tissue and its respective weighing factor (wT ), according to
ED = ∑
T
wT HT , (3.5)
thus representing the total body radiation risk. The tissue weighing factor (wT ) for thyroid gland is
0,04. In Appendix B, Table B.1 presents the weighing factors for some others organs and tissues,
obtained from Directive L 013, Official Journal of the European Union (OJEU), on 17th January
2014 [4].
Kerma
Kerma, K, is an acronym for kinetic energy of radiation produced per unit mass and takes the
form:
K =
dEtr
dm
, (3.6)
where dEtr is the average energy transferred to the secondary charged particles, as a result of
photon interaction in matter of mass dm.
Under charged particle equilibrium, which exists when in an incremental volume, for every
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charged particle with a certain kinetic energy leaving the volume, another with the same charac-
teristics enters the volume, absorbed dose and kerma are equal. This condition is closely achieved
in many practical situations [55].
Exposure
Exposure, X, is related to the ability of photons to ionise air and thus used to specify the
radiation field of γ and X-ray photons. It is defined as the absolute value of the ion charge of one
sign, dQ, produced anywhere in air by the complete stoppage of all light charged particles, except
those produced by bremsstrahlung, that are liberated in an incremental volume of air, per unit mass
of air in that volume, dmair [55], then
X =
dQ
dmair
. (3.7)
The SI unit is coulombs per kilogram (C kg-1).
Exposure and kerma in air are closely related, however, while K measures the kinetic energy of
the secondary electrons, X measures de ionisation caused by interaction of those electrons with air.
Exposure rate constant
Exposure rate constant (ERC or Γ), characterises the energy transferred to the air by the pho-
tons emitted by a radioactive source. This quantity can also be called specific gamma ray constant,
among a variety of other names.
For a particular point source of radioactivity, Γ relates its associated activity (A) to the exposure
dose rate (δD/δT ) in air, at a given distance (d) from the source:
δD
δT
= Γ
A
d2
. (3.8)
3.3 Health Physics
In this section, the absorbing medium is assumed to be the biological tissue. As radiation passes
through it, interactions with ambient atoms occur, leading to chemical free radical production that
may react with cell biomolecules. The damage extent of these reactions on the cells and how they
affect the organism is not easily determined and this is the reason why radiological protection
measures should be implemented.
The biological effects of ionising radiation (IR) depends on both exposure and duration of
exposure [55]. The cumulative exposure may trigger two types of biological effects: deterministic
and stochastic. The first are caused by acute, life-threatening exposure leading to a decrease or loss
of organ function due to cell damage or death. The high energy content in IR is strong enough to
disrupt chemical bonds throughout the cell, damaging the DNA molecules and leading to cellular
dysfunction and ultimately cell death [20]. Cell death is triggered when damage in the double
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strand of DNA is repaired incorrectly or it is not repaired at all. Thus, when trying to activate
mitoses, cells undergo apoptosis, that is, natural programmed cell death.
However, a pathological dysfunction is only clinically observable when a large number of
cells is damaged, so it is possible to define a threshold, from which the effects are visible [57].
For example, the aim of thyroid cancer treatment is to destroy remnant thyroid tissue while not
affecting other organs in such a way that deterministic effects occur. This is possible due to the
capacity of thyroid cells to take up iodine.
Stochastic effects result from alterations in cells that retain their ability to divide, from minor
acute or low-level exposure. These modifications initiate a malignant transformation leading to the
development of a malignant clone and eventually to a clinically observable cancer. If germ cells
are irradiated, genetic effects may result [57]. For stochastic effects no threshold dose is assumed
and the probability of their occurrence is proportional to the dose, which should be kept as low as
possible. Effective dose (ED) is the most common dose measure used for comparing the risk of
stochastic effects (See Section 3.2.2).
Following 131I decay both β -particles and γ-rays are emitted. The first particles represent the
highest contribution to the success of the treatment, while the majority of the second ones, leave
the patient via the skin surface. The predominant interaction of γ-ray photons with soft tissue is
by Compton scattering [2].
Because virtually no β -particles escape from large tumor deposits where 131I is concentrated,
large doses of 131I may be given without damaging surrounding tissues. In addition, due to the
surgical removal of thyroid tissue, elimination of radioactivity resultant from the administration
of 131I occurs at a faster rate, thereby allowing higher doses treatments [58]. However, from a
radiation protection point of view, the best strategy is to always use a radiation dose as low as
possible that will not compromise the desired effects and benefits for patients.
Studies show that 53% of patients achieved ablation after a single administration of 131I up
to 1110 MBq (30 mCi). This value increases up to 86% if the activity of the administered dose
corresponds to 3700 MBq (100 mCi) [59]. Currently, standard therapy with 131I is given as fixed
doses or activities. Small cancers confined to thyroid may receive the lowest dose (1110 MBq
or 30 mCi) while more advanced cancers with metastases at distance receive higher doses (up to
7400 MBq or 200 mCi) [6, 26].The retained activity, however, changes over time. This quantity
depends on the administered activity, the mass and function of the thyroid tissue and the rate of
clearance, that can be stimulated by patient’s hydration and renal function [52].
After the administration, the patient is kept in an isolated unit with a single-bed with dedicated
toilet and ablution facilities, until the radiation dose rate drops below 30 µSv/h [60]. This amount
is strongly influenced by thyroid mass, patient orientation and biodistribution of the radiophar-
maceutical within the organism (see Figure 2.7) and should be measured with a portable survey
meter held at a distance of 1 m anterior to the patient’s neck. Notwithstanding, radiation exposure
may also result from contacting with 131I that was secreted by the treated patient. The majority of
26 Radiological Protection
the excretion occurs via urination, but small amounts of the radionuclide may also be present in
saliva, tears and other body fluids.
Exposure rates should also be measured in strategic points, such as, at the bedside, at the
doorway and in the neighboring rooms of the hospital unit in accordance with the occupancy
factor (present in Table 3.1).
Table 3.1: Occupancy factor relative to members of the public [61].
Value Occupation
1 Areas with total occupation
1/4 Areas with partial occupation
1/16 Areas of occasional occupation
Total body retention or external radiation dose rate should thereby be measured before dis-
charge of the patient, to ensure that regulatory criteria for radioprotection are met, that will be
explained thoroughly in the next section.
3.4 Review of National Regulation
The European Atomic Energy Community (EURATOM) established basic safety standards related
to the health protection, of workers and members of the public, against the dangers arising from
ionising radiation, that were adopted by Portuguese national legislation.
According to D.L. no165/2002, on 17th July 2002 [62], an “exposed worker” is a person,
either self-employed or working under an employer, subjected to exposure at work from practices
covered by the mentioned Directive, that are likely to result in doses higher than the fixed threshold
dose established for the members of the public. In D.L. no222/2008, on 17th July 2008 [63], which
is in accordance with Directive L 013, Official Journal of the European Union (OJEU), on 17th
January 2014 [4], the effective dose (ED) threshold for exposed workers is established as 100 mSv
per five years in a row, provided that this amount does not exceed the maximum value of 50 mSv
in each year. For a member of the public the limit dose is 1 mSv per year. This information is
summarised in Table 3.2. In case of pregnancy, the limit should not exceed 1 mSv during the
pregnancy period, especially for the unborn child.
Table 3.2: Effective dose threshold (ED, in mSv) for exposed workers and members of the public,
per year and for a period of 5 years in a row [63].
1 year 5 years
Exposed worker 50 100
Member of the public 1 5
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Concerning partial body exposure, the equivalent dose (HT) threshold for the lens of the eyes,
skin, hands, forearms, feet and ankles are also established in the same Directive for both exposed
workers and members of the public, which can be consulted in Table 3.3.
Table 3.3: Equivalent dose threshold (HT, in mSv) for exposed workers and members of the public,
for a period of 1 year [4].
Eyes’ lens Skin Hands, forearms, feet and ankles
Exposed worker 50 500 500
Member of the public 15 50
A unit intended for the administration of radiation for therapy, should also obey to dose cons-
traints, according to the same Directive. Therefore, a distinction shall be made between supervised
areas and controlled areas. That is, areas in which it is possible that exposure to which workers
are subjected can exceed one-tenth (from 2 to 6 mSv/year) or three-tenths (from 6 mSv/year),
respectively, of the dose limits established for exposed workers. Therefore, supervised areas are
planned for members of the public and non-exposed workers and controlled areas for exposed
workers. For the first one the limit is 1 mSv/year or 0,02 mSv/week and, for the second one, the
limit is 20 mSv/year or 0,4 mSv/week (Table 3.4).
Table 3.4: Dose limit (mSv), per week and per year, for controlled areas and supervised areas [4].
1 week 1 year
Controlled area (⇒ Exposed worker) 0,4 20
Supervised area (⇒Member of the public) 0,02 1
According to D.L. no180/2002, on 8th August 2002 [61], a unit for inpatient therapy, beyond
hospital standards, must also include rooms with radiation protection, taking into account the
maximum activity estimated for each room. These rooms must comprise a single bed, toilet and
restricted furniture easy cleanable. After discharge of the patient, the room must be decontami-
nated.
In order to ensure radiation safety conditions, the design of these units should take into ac-
count the location, configuration, number of rooms and their dimensions. Adequate protection is
obtained by controlling the workers distance to the radiation source, the exposure time and the
existing shielding, which must take into account the proper location of the radioactive source and
the type, energy and directions of the irradiation [61].
For the purpose of this work, the unit is meant to accommodate a nuclear medicine service
valence, in where patients diagnosed with thyroid carcinoma will be administered with radioactive
iodine, which implies hospitalisation due to the high doses applied.
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3.5 Radiation Safety Factors
There are four major methods by which radiation exposure can be minimised.
Radiation levels decrease with the square of the distance from the point source of radiation,
given by the inverse square law. Therefore, the exposure dose rate (δD/δT )2 at distance d2 is
given by Equation 3.9, knowing that at distance d1 the exposure rate from the same radioactive
source is (δD/δT )1 . (
δD
δT
)
2
=
(
δD
δT
)
1
(
d1
d2
)2
(3.9)
Intuitively, radiation dose is directly proportional to duration of exposure, therefore exposure
time should be minimised. However, the human body does not irradiate at a constant rate, thereby
knowledge of both the exposure rate and how it changes over time are important elements in
minimising personnel exposure.
Another factor is related to contamination control methods that are planned to avoid radioac-
tive materials entering in contact with personnel and its spread. Adequate protection includes
handling precautions and disposable materials. The former must be discarded into designated ra-
dioactive waste containers, so that decay to background levels is allowed. As 131I is a volatile
radionuclide, it should be stored in an exhaust fume hood in order to avoid air contamination and
subsequent inhalation.
The last factor has a prominent role concerning the purpose of this work. The use of proper
shielding should be used to diminish radiation exposure levels to the unit sorrouding areas. The
shielding characteristics, such as material type, thickness and location, depend on the radiation
type, energy and intensity, as well as, on the geometry and location of the radiation source [2].
This barrier aims to ideally block or attenuate the radiation emitted by 131I after administration by
the patient.
3.6 Shielding Design
After administration of 131I for thyroid cancer therapy, the patient becomes a potential radiation
hazard to others and should be isolated if the activity administered is higher than 740 MBq (20
mCi) and while the radiation dose rate is higher than 30 µSv/h [60].
Isolation aims to allow radiation exposure to drop to national legislation acceptable levels and
below, following the ALARA principle, that is, to reduce radiation exposure to levels that are as
low as reasonably achievable.
The dose limits established by national and European agencies are indicators of the maximum
dose amount acceptable resultant from exposure to ionising radiation, under particular conditions.
All entities are required to employ good health physics practices and radiation safety programs to
ensure that radiation exposure is kept as low as reasonably achievable (ALARA). This principle
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represents a commitment between both employee and employer to minimise radiation exposure to
staff and general public.
Thereupon, the radiotherapeutic room should follow a judicious shielding design plan, with
the goal of minimising radiation exposure to those limits highlighted in Section 3.4.
The design requires thorough characterisation of the radiation source and must consider the
maximum possible dose, so the type and configuration of the necessary shielding for the most
extreme situation could be determined. As it was already stated, 131I emits both β− particles and γ
radiation during decay. While β particle present high ionising capability, and for this reason, suc-
cessfully harming cancerous cells, γ radiation, constituted of photons, possess greater penetrating
power and for this, poses an external source of radiation for others and consequently, should be
blocked or attenuated.
Shield properties should be well understood as well as radiation interaction with those mate-
rials, since the type and probability of an interaction depend on the photon’s energy, hν , and on
the absorber’s atomic number Z and density ρ . The shield design should be optimised in order to
minimise weight, volume and cost. These considerations represent the exact aim of this work and
will be assessed in the next sections.
3.6.1 Radiation Sources
If the volume of the source is sufficiently small, that is, if the source’s dimensions are too small
when comparing to the dimensions of the attenuating medium between the source and the dose
point, and there is negligible interaction of radiation with the matter in the source volume, then the
real source can be mathematically treated as a point source [55, 56].
A point source may depend on energy, direction and time. However, in most of the shielding
practices, time is not treated as an independent variable, since the time delay between a change in
the source and the consequential change in the radiation field is normally insignificant. In addition,
radioisotope sources are certainly isotropic, meaning that they radiate uniformly in all directions
throughout a 4pi geometry, and 131I is no exception. Consequently, source characterization requires
only knowledge of energy. In this particular case, energy dependence is discrete.
3.6.2 Attenuation of Gamma and X-rays
Attenuation is the removal of photons from a beam as it crosses a particular material, by the
interactions mechanisms already discussed in Section 3.1.2.
Briefly, when γ radiation is incident on a finite thickness of material, there is the probability
that it will interact with the material and be attenuated, depending on the photon energy and on
the Z number and density of the material.
Photoelectric effect, Compton scattering and pair production represent the interactions of ma-
jor importance, followed by Rayleigh and Thomson scattering. When low energy photons are
involved, photoelectric effect is the preferred interaction. With increasing energy, Compton scat-
tering prevails. Only at very high photon energies (> 1,02 MeV) would pair production contribute
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to attenuation. Rayleigh scattering plays no role in radiation dosimetry, since no energy is trans-
ferred to charged particles. Consequently, it is often ignored in shielding barrier calculations.
As a consequence of these interactions, secondary X-rays production may occur (Section
3.1.3). But, because in most shielding applications X-rays have usually energies ≤100 keV, they
are easily attenuated by any shield adequate for the primary radiation, and hence often neglected
in analyses involving higher energy photons [55].
Charged particle interactions are not considered in shielding situations, even if they were emit-
ted by the radioactive source and its slow down in the material would produce bremsstrahlung,
because the gamma and X ray photons are usually more numerous and penetrating than the
bremsstrahlung.
The most important parameter used in the characterisation of gamma and X-ray penetration
into absorbing media is the linear attenuation coefficient µ (typically cm-1), which describes the
fraction of photons removed from a monoenergetic beam of X- or gamma rays, per unit thickness.
This coefficient depends on energy hν of the photon and on the atomic number Z of the absorber.
In a homogeneous medium, the linear attenuation coefficient is constant for the same energy.
It can be determined using a narrowly collimated source of monoenergetic photons that traverses
a slab of absorber material with thickness x until it reaches a narrowly collimated detector (narrow
beam geometry). The material decreases the initial intensity, I(0), exponentially according to
Beer’s Law:
I(x) = I(0)e−µx. (3.10)
Consequently, the exposure dose rate decrease in the same manner and Equation 3.10 can be
rewritten as
δD f
δT
=
δDi
δT
e−µx, (3.11)
where (δD f /δT ) represents the final dose rate resultant from the attenuation of the initial dose
rate (δDi/δT ), as a consequence of crossing a material with thickness x, that reached the detector.
Thus, (δD f /δT ) is the dose resultant from the primary photons, that is, photons that crossed the
material without interacting.
For a given thickness, the probability of interaction is dependent on the number of atoms per
volume. In order to overcome this dependency, the linear attenuation coefficient can be normalised
to unit density of the absorbing material. This coefficient is called the mass attenuation coefficient
µm (cm2/g). For a compound of mixture of materials, the mass attenuation coefficient is approxi-
mated by the summation of a weighted average of its constituents:
µ
ρ
= ∑
i
wi
µi
ρi
, (3.12)
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where wi is the proportion by weight of the i-th constituent and µi/ρi is the mass attenuation
coefficient of the i-th constituent.
These coefficients have specific values for a given photon energy hν and absorber atomic
number Z, with density ρ . They result from the sum of values for all the individual interactions
mentioned before, hence
µ = τ+σR +σC +κ, (3.13)
µm =
µ
ρ
=
τ+σR +σC +κ
ρ
, (3.14)
where τ is the linear attenuation coefficient for photoelectric effect, σR is the linear attenuation
coefficient for Rayleigh scattering, σC is the linear attenuation coefficient for Compton scattering
and κ is the linear attenuation coefficient for pair production.
3.6.3 Characteristic Absorber Thicknesses
Mean free path is the thickness necessary to attenuate the beam intensity to 1/e = 0,368(36,8%).
The photon mean free path is the average distance a photon travels through a given absorber before
undergoing an interaction. The thickness of the material at which the radiation intensity is reduced
by half is the material’s half-value layer (HVL) [64]. Similarly, the tenth-value layer (TVL) is the
thickness necessary to reduce the initial intensity to a tenth of its value. By knowing µHVL
and/or µTVL of a material for a given energy, it is possible to calculate the necessary thickness to
efficiently shield a nuclear medicine unit, respectively, according to
µHVL =
ln2
HVL
, (3.15)
µTVL =
ln10
TVL
. (3.16)
3.6.4 Build-up Effect
In radiation protection, particularly in shielding design, it is used a broad beam geometry, in
contrast to the narrow beam. In this case, the beam is not collimated and consequently, the final
dose rate equals B.(δD f /δT ), where B is the build-up factor that accounts for the secondary
photons that are scattered from the absorber and δD f /δT the final dose rate in a narrow beam
geometry. Thereby,
δD fB
δT
= B
δDi
δT
e−µx. (3.17)
For a monoenergetic gamma emitter, the build-up factor represents the ratio of total dose (pri-
mary and secondary photons) to the dose from primary photons alone. It is a dimensionless quan-
tity, which magnitude varies widely, ranging from a minimum of 1, where δD fB/δT = δD f /δT ,
to very large values, depending on photon energy and shielding characteristics (material and thick-
ness), geometry and distance to the radioactive source [56].
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According to Groth, 1998 [60], for a patient submitted to radioiodine treatment in a typical
isolation room, B lies between 1,25 and 1,35 (assuming thyroid area from 400× 300 mm2 to
700×300 mm2).
3.6.5 Shielding Materials
After source characterisation, comprehension of possible photon interactions and review of regu-
latory criteria concerning acceptable dose limits, there is a parameter that still needs to be taken
into account that is materials’ evaluation and geometry. This concerns assessment of elemental
composition and densities of material components, as well as, its placement on the room. Also,
according to the radiation types emitted by the radioactive source, homogeneous or layered ma-
terials might be demanded. This also represents a shield-optimisation problem where decision
should be made towards number and thicknesses of the layers.
According to Directive L 013, OJEU, on 17th January 2014 [4], a building material should
be designed to be permanently incorporated in a building or parts thereof, since it influences its
performance regarding exposure of its occupants to IR.
Air is assumed to be a natural shielding material. Dry air, at 1 atmosphere and 20o has a
density of 0,00120 g cm-3 [55]. Ordinarily ideal gas laws should be applied to recalculate density
for different temperature, pressure and humidity.
High density concrete is often used to provide greater attenuation for a given thickness. This
is a highly desirable material since it gathers reasonable cost, compressive strength, ease of place-
ment and effectiveness in gamma ray attenuation. Reinforcing steel provides tensile strength and
adds density to concrete.
Metallic materials are also used for shielding purposes, namely lead, allow steel and stainless
steel. Lead is the most frequently used shielding material, alongside with concrete. It has low
strength, low melting point and high density (ρ = 11,350 g cm-3 [65]).
To sum up, β radiation emitted by 131I is practically restricted to the thyroid gland and hence,
will hardly reach the shielding walls. The distance between the radioactive gland and the walls
is relatively large when compared to the thyroid dimensions and β particles do not have enough
penetrating power to travel a distance so far.
However, primary radiation may induce secondary energetic particles as a result of the inter-
actions processes, which in turn may also produce other particles, with lower and lower energies.
Therefore, it is necessary to be aware of the dependence of the various fundamental interaction
processes on particle energy and on absorber atomic number (Z), to understand these cascade
processes.
Therefore, considering photon radiation, materials with higher Z numbers are necessary. The
most commonly used materials for the shielding of this radiation are lead and concrete. The
attenuation provided by a 190 mm core-filled concrete block wall is equivalent to a 13 mm lead
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sheet for 131I [66]. This evidence should be taken into consideration in the shielding optimisation
assessment.
The best shielding for β particles is a double-layered shield, made by a first material with a
small Z, such as plastic or glass, followed by a second material with higher Z, such as lead. This
shield aims to attenuate high-energy beta radiation while minimising bremsstrahlung [2, 44].
Also, the shielding plan for a nuclear medicine unit for thyroid carcinoma therapy must con-
sider the number of treatments to be performed, the activity of 131I and the occupancy factors
within the room and for adjacent areas. Protocols for thyroid cancer treatment with 131I may vary
from country to country and even within the same country, from hospital to hospital, however
thyroid mass and biokinetics of 131I in the patient thyroid should always be assessed so a more
precise absorbed dose could be computed.
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Chapter 4
Radiation Source Properties
4.1 Decay Analysis
Depending on the radiopharmaceutical, the production site may not correspond to the site where
the radioisotope will be used.
In this work, 131I was delivered to the nuclear medicine service where the suitable equipments
for the measurement of the initial activity are present and only after, it was transferred to the
hospital unit intended for 131I administration. Therefore, it was necessary to evaluate the de-
cay behaviour of the radioisotope, within the actual conditions, to be certain that it followed the
theoretical assumptions, since this information will be needed in future considerations. This ex-
perimental decay analysis was performed for three radioisotopes (99mTc, 67Ga and 131I) that will
be used in posterior experiments. This procedure was necessary since the radiation sources were
transferred to the site where the measurements were held after production in a different location.
A priori, the known physical characteristics of interest for each radioisotope were gathered
and assumed as the reference values (Table 4.1), with which the determined experimental values
were compared.
Table 4.1: Physical characteristics relative to 99mTc, 67Ga, 131I decay [43].
Radionuclide t1/2 λ
99mTc 6,0067 h 0,1154 h-1
67Ga 3,2613 d 0,2125 d-1
131I 8,0233 d 0,0864 d-1
Briefly, 99mTc half-life (t1/2) is 6,0067 hours and the decay constant (λ ) is 0,1154 h-1 [43]. As
already explained, these quantities can be related by Equation 1.3. 67Ga has a t1/2 of 3,2613 days,
and therefore, a λ of 0,2125 d-1 [43]. 131I has a radioactive decay half-life of 8,0233 days [43],
which means a decay constant of 0,0864 d-1.
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The activity of the radionuclides was measured at different times: immediately after prepara-
tion (A(0)) and throughout the measurement (A(t)), with recourse to two different dose calibrators:
Dose Calibrator 1 (DC1) - PTW, Curiementor 3, s.n. 1110731, with manufactured data at March,
2001 - and Dose Calibrator 2 (DC2) - LemerPax, Posidose, s.n. 00905, with manufactured data
at June, 2010. DC1 registers the activity in its vicinity, so there is the need to acquire the residual
activity and then subtract this value to A(t). The second dose calibrator does this calculation auto-
matically after manual calibration every time a measure is performed. This is the main difference
between the two dose calibrators. Both calibrators have an associated error of ±0,00005 mCi.
The results were manipulated with Excel R©, according to
lnA(t) = lnA(0)−λ t, (4.1)
where A(0) represents the initial activity, at time t = 0, A(t) the measured activity at the time t
the values were registered and λ the experimental decay constant for each dose calibrator. This
expression results from the manipulation of the fundamental decay equation (Equation 1.2) that
shows the exponential radioactive decay. The minus sign indicates that the number of radioactive
atoms decaying per unit of time decreases with time. Following the logarithmic representation,
λ is easily identified as the slope of the curve. For each radioisotope, the experimental λ is the
average of the decay constants obtained from the measurements performed with the two dose cali-
brators followed by application of appropriate unit conversions. The respective half-life (t1/2) was
obtained after application of Equation 1.3.
As expected, the plot of the activities as a function of time results in an exponential relation-
ship in which the total activity asymptotically approaches zero (in Appendix C in Table C.1 –
Table C.3). Graphical representations were obtained following representation of Equation 4.1, as
can be seen in Appendix C in Figure C.1 – Figure C.3.
Both tabulated and experimental values, as well as the associated relative error, are shown in
Table 4.2. All the obtained experimental values are in accordance with literature [43], despite a
minimum deviation that may be justified by the degree of sensitivity of each calibrator and due to
the influence from the natural background radiation that is also present in the fume hood where
the measurements were held.
Table 4.2: Experimental half-life time (t1/2) and decay values (λ ) and the error relative to the
tabulated values [43].
99mTc 67Ga 131I
t1/2 λ t1/2 λ t1/2 λ
Tabulated 6,0067 h 0,1154 h-1 3,2613 d 0,2125 d-1 8,0233 d 0,0864 d-1
Experimental 5,9872 h 0,1158 h-1 3,3134 d 0,2092 d-1 8,4082 d 0,0825 d-1
± Relative error (%) 0,3245 0,3393 1,5975 1,5529 4,7978 4,5718
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As the difference between reference and experimental values of λ and t1/2 for all the radionu-
clides is too narrow to be considered, the production of the radionuclides and acquisition of initial
activity in an external nuclear medicine service followed by transfer to the therapy unit is suitable
for the posterior measurements.
4.2 Exposure Rate Constant Determination
The exposure rate constant (ERC or Γ) is an important factor needed for routine calculation in
medical physics regarding radiation safety and medical uses of radionuclides, since it characterises
the energy transferred to the air by the photons emitted by a radioactive source. For an isotropic
point source of gamma radiation, the ERC is given by Equation 3.8, where it is denoted by Γ. The
purpose of this step was to determine experimentally the ERC for 99mTc, 67Ga and 131I, in order
to comprehend which factors affect this quantity and in which amount. A theoretical calculation
was also performed, according to Smith and Stabin method [67], for comparison purposes. Since
published data may present some disagreement, this quantity was recalculated in this work from
recently updated data.
4.2.1 Theoretically
According to Stabin and Michael, 2007 [68], in terms of the decay spectrum of a nuclide, ERC
can be written as
Γδ =
1
4pi∑i
(
µen
ρ
)
i
YiEi, (4.2)
where µen/ρ represents the mass-energy absorption coefficient in air for photons of energy E
emitted by the nuclide, during the decay process, with a certain yield Y . i corresponds to each
photon energy, which contribution must be summed up. δ is the minimum cut-off energy. This
value determines the minimum energy photon that can contribute to the exposure.
All the characteristic energies Ei of the emitted photons and their corresponding yields Yi were
obtained from NuDat 2.6, which is a database developed by the National Nuclear Data Center [69].
More specifically, information about 99mTc was originating from Browne and Tuli, 2011, [70];
about 67Ga from Huo et al., 2005, [71]; and about 131I from Khazov et al., 2006, [72]. As in Smith
and Stabin, 2012 [67], only values equal or above 15 keV (δ = 15 keV) and yields of at least 10−4
were considered. The reason for neglecting these energies is due to the fact that in practice, these
emissions almost never contribute to dose given the rapid attenuation of these photons [67].
The µen/ρ for the photons with energy E were taken by interpolation of Hubbell and Seltzer,
1996, [65] data.
The appropriate unit conversions were applied so the final units were (µSv m2)/(MBq h).
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Comparison of ERC values, for the selected radionuclides, calculated theoretically to those
from Smith and Stabin, 2012 [67], Unger and Trubey, 1982 [73], Tschurlovits et al., 1992 [74] and
Ninkovic et al., 2005 [75] is shown in Table 4.3.
Table 4.3: Comparison of the calculated ERC values for the selected radionuclides.
Exposure rate constant (µSv m2)/(MBq h)
Radionuclides This work Smith and Stabin, Unger and Trubey, Ninkovic et al.,
2012 [67] 1982 [73] 2005 [75]
99mTc 0,020084 0,020600 0,033200 0,014100
67Ga 0,019949 0,020800 0,030000 0,019450
131I 0,055197 0,056500 0,076400 0,052200
The values obtained in this work were generally lower than the values found in the literature,
except for Ninkovic et al., 2005 [75]. The reason for the lower values obtained by Ninkovic et
al., 2005, is probably justified by the fact that its method only considers photon energies above
20 keV.
Relatively to Unger and Trubey, 1982 [73] because they included emissions down to 10 keV,
the resultant values were higher than the ones obtained in this work. Also, instead of using ab-
sorption coefficients, Unger and Trubey used a fitted function of dose rate per unit flux density.
Therefore, the difference in the results may be related to differences in methodology. The
higher the minimum cut-off energy (δ ), the lower the ERC value.
The ERC values obtained in the present work are very similar to the ones provided by Smith
and Stabin, 2012 [67], since they were calculated following the same methodology. Minor varia-
tions arise from differences in source data.
4.2.2 Experimentally
The experimental determination of ERC was conducted in a wide open area, without near barriers,
for each radionuclide with initial activities present at Table D.1. The radioactive decay was taken
into account based on the assumptions presented in Section 4.1.
The exposure dose rate (δD/δT ) was acquired at strategic points, according to Figure 4.1,
with a portable dosimeter (AT1121, Atomtex R©- see Appendix E for detailed specifications)
enabled to acquire X and gamma radiation every second. By knowing the distance d between
the radioactive source and the dosimeter and the activity at the time of the measurement A(t)
(Equation 1.2), the calculation of Γ was direct, following transformation of Equation 3.8:
Γ =
d2
A(t)
δD
δT
. (4.3)
The first round of measurements was performed with the radioactive source placed at 1 m from
the floor (Figure 4.1a).
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In order to quantify the influence of the increasing distance, d, the measurer was placed at 1 m
(P1, P4, P7), at 2 m (P2, P5, P8) and at 3 m (P3, P6, P9) from the source, at the same height. For
each distance, measurements were acquired in three different points, with the purpose of studying
the horizontal angular influence: at 0o (P1, P2, P3), at 120o (P4, P5, P6) and at 240o (P7, P8, P9).
The vertical angular influence was also accounted by measuring the dose rate, relatively to the
source height, at -46o or 0 m height, that is, on the floor (P10, P11, P20) and at 25o or 1,5 m height
(P12, P13).
Figure 4.1: Distribution scheme of the measurement points with the radioactive source placed at
a) 1 m from the floor (z=1) and b) on the floor (z=0). The schemes were obtained using Matlab.
The second round was performed with the radioactive source placed on the floor (0 m height),
as schematised in Figure 4.1b. The same evaluation was performed.
Once more, the behaviour of the exposure dose rate was analysed with increasing distance: at
1 m (P14, P16), at 2 m (P15) and at 3 m (P17). The horizontal angular influence was established
at 0o (P14, P15, P16) and at 120o (P16). Finally, the vertical angular influence was assessed by
placing the dosimeter at 0o or 0 m height (P14), at 46o or 1 m height (P18) and at 56o or 1,5 m
height (P19).
After each five minute point measurement, the data was exported to the PC and the values
analysed as follows. Only values associated to a data acquisition error equal or below 5% were
considered.
First, with the purpose of calculating the exact activity at the time of the measurement, A(t),
the time elapsed between t = 0 (time when the initial activity, A(0), was registered) and the ac-
tual time of the measurement, was calculated. Then, following the fundamental decay equation
(Equation 1.2), A(t) was obtained. After subtracting the background dose rate to the dose rate
measured, Γ was calculated in accordance to Equation 4.3, with being (µSv m2)/(MBq h) the
final units.
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It was expected that despite variation of the measurement conditions, the ERC value remained,
as the name implies, constant. However, that was not the case as it will be discussed thoroughly.
The purpose of this study is related to the fact that the assessment that will be conducted in the
room intended for iodine radiotherapy will imply acquisition of exposure dose rates in strategic
points arranged in different spatial locations. Moreover, the dosimeter will be placed immediately
before and after the barrier. Therefore, it was crucial to determine the radiation behaviour in an
open space without interference of close barriers to support the evaluation within the room.
Horizontal angular influence
Acquisition of all the points from P1 to P9 was only performed for 99mTc, since, as one can
see by looking at Figure F.1A, the variation of the horizontal angle while keeping the distance
to the source, does not seem to alter significantly the final ERC value, which corroborates the
principle of isotropic source (see Section 3.6.1). Simultaneously, when the measurement is con-
ducted at the floor level, the same behaviour was verified. Thus, from now on, let consider the
average ± standard deviation of the separate measurements at the same distance to the source,
as follows: P1 = (P1, P4, P7); P2 = (P2, P5, P8); P3 = (P3, P6, P9); and P14 = (P14, P16). The
results are presented in Table 4.4. The horizontal angular influence was not assessed for the rest
of the radionuclides since one just assumed that the same behaviour was transversal to all the
radioactive species.
Table 4.4: ERC average value± standard deviation (SD) for 99mTc concerning an isotropic source.
Γ (µSv m2)/(MBq h) ±SD
P1 0,021166 0,000582
P2 0,025577 0,000516
P3 0,027972 0,001042
P14 0,020389 0,000184
However, when comparing Figure F.1A and F.1B, one can conclude that when the measure-
ments are performed on the floor, the value for ERC is slightly lower. This may be justified by the
fact that only half of the air volume is available for the radiation to travel.
Distance influence
In this procedure the dosimeter and the radioisotope were at the same height. Through analysis
of Figure F.2, one can see that globally, for all the radioactive species, the increasing distance
results in an increasing ERC. When higher energies are involved, the rise with distance is more
noticeable. Again, when on the floor, the ERC is lower than when at 1 m height, as well as the
augmentation.
This behaviour is shown through the correlation functions of Table 4.5. One can observe that,
for the same radioactive source, the ratio between the powers at z=0 over z=1 is approximately
0,5 which corroborates the assumption that at the floor level, the source is no longer considered
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isotropic since only half of the air volume is available for the radiation to propagate.
Table 4.5: Correlation functions, y(d)=adb, illustrating the behaviour of Γ in (µSv m2)/(MBq h)
with distance d in m, for 99mTc, 67Ga and 131I, at 1 m (z=1) and 0 m (z=0). R2 is the correlation
coefficient, obtained with Excel R©.
99mTc 67Ga 131I
z (m) y R2 y R2 y R2
1 0,0212d0,2559 0,9971 0,0311d0,1923 1 0,0606d0,1893 0,9999
0 0,0204d0,1044 1 0,0294d0,0971 0,9981 0,0590d0,0960 0,9997
Vertical angular influence
Figure F.3 shows how ERC varies with alteration on the vertical height of dosimeter. In Figure
F.3a the radioactive source is placed 1 m while in Figure F.3b the source is placed on the floor.
Once more, the greater the distance between the measurer and the source, that is, the greater the
angular displacement, the higher is ERC. This trend is visible for all the radionuclides. However
the correlation functions of Table 4.5 do not represent the best approximation for this situation,
as it was expected. Even the best approximation has an associated correlation coefficient to some
extent far from 1 (Table 4.6). This may be justified by the fact that different geometries are mixed
in the analysis: 4pi geometry when the measurement is performed away from the floor and 2pi
when on the floor; and due to differences in the sensibility of the dosimetry concerning a vertical
plane. In the dosimeter specifications, only information about anisotropy in the horizontal plane
is given (see Appendix E).
Table 4.6: Correlation functions, y(d)=adb, illustrating the behaviour of Γ in (µSv m2)/(MBq h)
with vertical distance d in m, when 99mTc, 67Ga and 131I are placed at 1 m (z=1) and 0 m (z=0).
R2 is the correlation coefficient, obtained with Excel R©.
99mTc 67Ga 131I
z (m) y R2 y R2 y R2
1 0,0209d0,201 0,9271 0,0308d0,0977 0,841 0,0602d0,1496 0,9507
0 0,0208d0,4056 0,9517 0,03d0,3236 0,9405 0,0597d0,2972 0,9676
Build-up effect
As was possible to notice throughout the previous figures, ERC values for measurements per-
formed on the floor were systematically smaller than the ones performed at 1 m height, for the
same distance. This can be more clearly noticed by looking at Figure F.4. As explained before,
this may be due to the different geometry available to irradiate, which results in less direct radia-
tion. Therefore, when the radioactive source is on the floor, ERC is lower.
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As the patient will spend most of his/her time on the bed, at approximately 1 m from the floor
and at the distance of 1 m from the closest wall, the ERC obtained from P1 was used as reference
for comparison purposes. In the case of 99mTc the reference value was the averaged P1. Table 4.7
shows a comparison between the experimental reference value and the one calculated according
to Stabin and Michael, 2007 [68] method. Globally, the experimental value is slightly higher than
the theoretical one, which is more evident for 67Ga. Nonetheless, one can say that the values are
in agreement.
Table 4.7: Comparison of the ERC calculated theoretically in this work to the value determined
after measuring the dose rate at the distance of 1 m from the radioactive source.
Exposure rate constant (µSv m2)/(MBq h)
Radionuclides Theoretical Experimental ±SD Ratio
99mTc 0,020084 0,021166 0,000582 0,95
67Ga 0,019949 0,031063 0,000007 0,64
131I 0,055197 0,060654 0,000149 0,91
One can conclude that both ERC determined theoretically and experimentally are in agreement
to those values found in literature. However, when altering the experimental conditions at which
the exposure dose rate is acquired, the resultant ERC does not remain constant. It was noticed that
ERC increases when the distance between the radioactive source and the dosimeter is raised. On
the other hand, ERC decreases when the measurement is performed at the floor level.
Chapter 5
Characterisation of the Unit Structure
Throughout this section, the unit-subject of this study will be referred as room no 401 (R401),
since it is the first room in the corridor located on the fourth floor. Considering that R401 is
located one floor above the new-borns floor, it was hypothesised the usability of room no 501
(R501) for accommodating the iodinetherapy treatment. At first glance, this room represent a
better option since it is not preceded by a floor occupied by a group of people highly sensible to
radiation.
Provided these considerations, the proper characterisation was conducted for both rooms fol-
lowing the exact same procedure, since, despite minor differences, both rooms presented the same
geometrical arrangement.
The aim of this stage is to determine the physical characteristics of the construction materials
present in the room structure. Each wall (floor and ceiling included), with thickness x, may be
formed by one unique material (homogeneous material) or by a set of different materials (the most
probable). As already explained (see Section 3.1.2), photon interactions with the absorbing media
depend on the characteristics thereof, but also on the photons’ energy, hν .
When traversing a material, the photon beam intensity is decreased depending on the mate-
rial’s thickness x and on the linear attenuation coefficient µ for a certain photon energy, according
to Equation 3.10. For this reason, this procedure was conducted with recourse to three gamma-ray
emitting radionuclides: 99mTc; 67Ga; and 131I, with distinct ranges of energy emission (Table 5.1).
The linear attenuation coefficient considered for each radioactive source mentioned is in fact re-
sulting from a weighted average concerning the yields at which the different energy amounts are
emitted. Therefore, at this point, there are four variables for each wall:
• thickness (x);
• weighted average linear attenuation coefficient to 99mTc (µ 99mT c);
• weighted average linear attenuation coefficient to 67Ga (µ 67Ga); and
• weighted average linear attenuation coefficient to 131I (µ 131I).
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Table 5.1: Most significant energy spectra for 99mTc, 67Ga and 131I (adapted from NuDat 2.6 [70,
71, 72]).
Radioisotope Energy (keV) Yield
99mTc 140,511 0,89
67Ga 93,310 0,39
184,576 0,21
300,217 0,17
393,527 0,05
131I 284,305 0,06
364,489 0,82
636,989 0,07
722,911 0,02
A round of measurements was performed for each of these radionuclides. In each round, the
exposure dose rates were measured when the radioisotopes were placed at two distinct strategic
points, at a known distance from the walls:
• Bed — where the patient will spend most of her/his time; and
• Toilet — where the patient will spend a considerably amount of time.
In each measurement of each round, after placement of the radionuclide in one of the strategic
points, a dosimeter (AT1121, Atomtex R©- see Appendix E for detailed specifications) was placed
immediately before and after the shielding barrier at distinct times, as schematised in Figure 5.1.
The attenuation provided by the barrier with thickness x, to a given radiation energy, was
calculated according to Equation 3.11, after measuring the exposure dose rate before (δDi/δT )
and after (δD f /δT ) the attenuation. Only values associated with an error less or equal to 5% were
considered in the average exposure dose rate calculation.
The calculated thickness does not correspond to the exact dimension of the barrier but to the
lead-equivalent thickness (in millimetres of lead, mmPb). That is, it was determined which thick-
ness of lead would provide the same attenuation to a given amount of energy as the heterogeneous
wall provides. The lead mass attenuation coefficients (µm) for the radionuclides’ energies were
obtained by interpolation of Hubbell and Seltzer, 1996 [65] data. Given that the lead density is
11,350 g cm-3, the linear attenuation coefficients (µ) were easily obtained. The points of interest
were distributed in the room in accordance to Figure 5.2. They were chosen based on the occu-
pancy factor and the operational actions developed in the surrounding areas. All points are marked
at 1 m from the floor, simulating the level at the patient bed, despite points F and G that represent
the ceiling and the floor, respectively, and O2 that represent the toilet.
All the measurements were conducted in R401 and R501. The only difference between the
rooms is that point C does not exist in R501. Since point C corresponds to a door, in R401 the
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Figure 5.1: Diagram for the measurement of the exposure dose rate, where: d is the distance
between the radioactive source and the interior limit of the barrier, where one detector (D1) is
located; a is the distance between the detector and the limit of the barrier (although it was neglected
since it represents a small distance when compared to d); x is the thickness of the barrier; h is the
distance between the floor and the detectors level. D2 is located in the exterior limit of the barrier,
at the same distance h from the floor as D1.
exposure dose rate before and after point E was measured twice, with that door closed (Ec@O1)
and opened (Eo@O1).
Electromagnetic radiation travels in a straight line, so equally important to the placement of
the strategic points is the distance between each one of them and the radioactive source of energy,
which is present in Table 5.2. This distance is represent in Figure 5.1 by d.
Table 5.2: Coordinates of all points of interest in R401, when the referential origin is placed
at O1 from Figure 5.2, and straight-line distances, d, from O1 and O2 to the points where the
measurements were held. All the distances are in cm.
Radioactive source Measurement point x y z d
A 0 100 100 100
B -200 -70 100 211,90
C -200 -170 100 262,49
O1 D 200 -321 100 378,21
E -437 -179 100 472,24
F 0 0 270 170
G 0 0 0 100
O2 D 200 -321 100 122,07
After obtaining the initial activities in Instituto CUF, the radionuclides were transferred to
Hospital CUF where the characterisation of the unit was performed. The activities at the start of
the measurement are shown in Table D.2. Again, this was validated in Section 4.1.
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Figure 5.2: Layout of the R401 therapy room with the marked points of interest: A — contact
point with another unit; B — contact point with machinery room; C — door that separates the
room itself from the hall that gives access to the room; D — bathroom and contact point with
another unit; E — entrance/exit door that separates the unit hall from the corridor, where other
patients, exposed workers and members of the public are with very high frequency; F — ceiling
and contact point with another unit in the floor immediately above; G — floor and contact point
with another unit in the floor immediately below; O1 — first reference point, located in the bed;
O2 — second reference point, located in the toilet. The distances are in cm.
The calculated weighted average linear attenuation coefficients for the three radionuclides are
presented in Table 5.3. The weighted average is used, instead of considering the attenuation
only to the higher energy, which for these radioisotopes are emitted with the least yields, in order
to avoid oversizing of the existent barrier. As one can see, the overall increase in the γ energy
emission results is a lower attenuation per centimetre of lead (cmPb), meaning that fewer photons
are removed from the incident beam.
After calculation of µx by applying Equation 3.11, such that:
µx = − ln(δD f /δDi), (5.1)
for each radioisotope, at each strategic point, the estimation of lead-equivalent thickness (x) was
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Table 5.3: Weighted average linear attenuation coefficients (cm-1) for lead, concerning the
weighted average gamma energy (keV) emitted during decay.
E (keV) µ (cm-1)
99mTc 140,511 30,473
67Ga 176,409 29,360
131I 386,185 3,285
straightforward. The results are present in Table 5.4 and Table 5.5, for R401 and R501, respec-
tively. The first thing that is noticed is that clearly the attenuation phenomenon strongly depends
on the photons energy.
Table 5.4: Lead-equivalent thickness (mmPb) in R401.
99mTc 67Ga 131I
R401 µx x (mmPb) µx x (mmPb) µx x (mmPb)
A@O1 5,64 1,85 2,16 0,73 1,33 4,04
B@O1 4,60 1,51 2,12 0,72 1,77 5,39
C@O1 4,15 1,36 1,65 0,56 1,02 3,11
D@O1 1,65 0,54 1,64 0,56 2,22 6,75
D@O2 5,40 1,77 2,62 0,89 1,73 5,26
Ec@O1 0,15 0,05 0,06 0,02 0,20 0,61
Eo@O1 0,30 0,10 0,12 0,04 0,28 0,85
Firstly, let one look at the behaviour of µx. As it is a negative logarithmic function (Equation
5.1), the lower δD f /δDi, the higher the resulting µx. As δD f /δDi represents the ratio between
the dose after and before the barrier, smaller ratios are indicators of greater attenuation. In the
limit, there is no attenuation. Thus, D f tends to equal Di and the ratio tends to 1 and µx to 0. Table
5.4 reflects this trend. In a general way, µx is systematically higher as the energy of the radioactive
source decreases (from 131I to 99mTc), meaning that for lower energies the attenuation is higher.
As the measurement points were chosen to be distributed along barriers edified with different
purposes, it was not expected they would attenuate the radiation in the same manner. However,
there is one exception: D@O1 and D@O2 refer to the same barrier, and for this reason the the-
oretical attenuation should have been the same, which was not verified. The difference between
both experiments is only the source placement: O1 at 1 m from the floor and O2 on the floor. As it
was already discussed in Section 4.2, the alteration in the radiation field geometry seems to affect
the exposure dose rate and consequently, the attenuation registered may not be representative.
Another unexpected outcome is related to point E. This barrier was subjected to two measure-
ments: the first in the presence of barrier C (Ec@O1) and the second in its absence (Eo@O1). In
the first situation, the energy is firstly attenuated by barrier C and then by barrier E; in the second,
the radiation travels in a straight line until attenuated by E. It was verified that in the former the
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exposure dose rate acquired at the interior limit of E was lower than in the latter (data not shown).
Therefore, theoretically barrier E should provide the same attenuation.
Since 131I is the radionuclide with wider range of energy emission, the lead-equivalent thick-
ness is naturally higher than for the others radioactive sources used. Then, even for a lower at-
tenuation, it is needed an absorber material with higher thickness than in the presence of lower
energies.
Table 5.5: Lead-equivalent thickness (mmPb) in R501.
67Ga 131I
R501 µx x (mmPb) µx x (mmPb)
A@O1 0,85 0,29 0,76 2,30
B@O1 0,75 0,25 0,70 2,14
D@O1 1,66 0,57 2,68 8,15
D@O2 3,54 1,20 3,01 9,16
Eo@O1 0,26 0,09 0,33 1,00
In R501, the same overall behaviour was verified (Table 5.5). In this room, the measurements
were only performed with 67Ga and 131I due to the higher energies associated.
Exposure dose rates at F and G are not shown since the values were relatively small and for
this reason neglected. The exposure dose rate at F was acquired when the radioactive source was
placed at O1 and O2, in order to quantify the attenuation provided by the ceiling. Due to the small
magnitude of the values, one just concluded that the ceiling provided the desired attenuation. This
assumption can also be applied to the floor, since they are both constituted by the same materials.
This experiment allowed concluding about the existent barriers of rooms 401 and 501 in lead-
equivalent thickness (mmPb). When comparing the results for both rooms, it is legitimate to admit
that the attenuation provided by the construction materials of R401 is higher which could mean
that some amount of shielding material was actually incorporated in the unit design.
Nonetheless, despite the attenuation provided, it was confirmed that the exposure dose rate
after the barriers was far from the regulatory values established by legislation, even in the presence
of the lowest energies. According to D.L. no222/2008, on 17th July 2008 [63] the maximum dose
limit for members of the public is 1 mSv/y, that is, 0,114 µSv/h.
Moreover, this experiment was conducted for small activities, while the radiotherapy may use
activities of 131I up to 200 mCi, which is twenty times higher, and according to Equation 3.8, the
exposure dose rate is directly proportional to the activity. Therefore, the shielding barriers should
be reinforced with an effective absorber material whose thickness was determined and explained
in the next section.
Chapter 6
Shielding Plan
Standard therapy with 131I is given as fixed activities. Small cancers confined to thyroid may
receive the lowest dose (1110 MBq or 30 mCi) while more advanced cancers with metastases at
distance receive higher doses (up to 7400 MBq or 200 mCi) [6, 26]. The retained activity, however,
changes over time. This quantity depends on the administered activity, the mass and function of
the thyroid tissue and the rate of clearance, that can be stimulated by patient’s hydration and renal
function [52].
Figure 6.1 shows a simulation of dose rate at 1 m and the radioiodine decay concerning the
calculated effective half-life (Te) of 7,52 days (Section 2.2.1.2) that takes into account both the
physical (t1/2) and the biological half-life (Tb). This simulation represents the worst case scenario
since the rate of clearance is not considered. If it was, 24h after administration of radioiodine, the
activity would probably correspond to 12–40% of initial value [47].
Figure 6.1: Simulation of the decay and expected dose rate (µSv/h at 1 m) for radioiodine with
initial activity of 7400 MBq (or 200 mCi), assuming a Te = 7,52 days.
After radioactive iodine (RAI) administration, the patient is kept in an isolated unit with a
single-bed with dedicated toilet and ablution facilities, until the radiation dose rate drops below 30
µSv/h [60]. This amount is strongly influenced by thyroid mass, patient orientation and biodistri-
bution of the radiopharmaceutical within the organism (see Figure 2.7) and should be measured
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with a portable survey meter held at a distance of 1 m anterior to the patient’s neck. This unit
should be prepared to minimise the radiation exposure to acceptable values, and for this reason the
shielding design should consider the extreme situation, that is, the highest dose administered and
an occupancy factor of 1 in the vicinity of the premises (Table 3.1).
For that, the exposure to 131I with activity of 7400 MBq (or 200 mCi) was simulated in the
strategic points defined before (Figure 5.2). Equation 3.8 allows estimating the exposure dose
rate that should be expected. Γ was calculated on the basis of the assumptions concluded from the
experiments performed before.
Thus, in the calculation of the exposure rate constant for the points measured when the ra-
dioactive source is at 1 m height from the floor (z=1), i.e., simulating the patient lying on the bed,
the function from Table 4.5 was used. When the radiation source was place on the floor (z=0),
simulating the patient in the toilet, the function from Table 4.6 was applied. The distance d repre-
sents the straight line distance between the radiation source and the each point, which are present
in Table 5.2. By knowing Γ, the expected exposure dose rate for each point was determined
following Equation 3.8. Considering the dose limit of 0,114 µSv/h as the maximum exposure
dose rate after the barriers, the necessary lead-equivalent thickness was determined by application
of Equation 5.1. The linear attenuation coefficient considered is present in Table 5.3. After
knowing the necessary thickness to attenuate the radiation in that extent, the existent thickness
was subtracted and the reinforcement determined.
The expected dose rate determined for 131I with initial activity of 7400 MBq (or 200 mCi) at
the strategic points is shown in Table 6.1. As one can see, the exposure rate within the unit will
be extremely high. Thus, in order to minimise the exposure on the outer side of the barriers to the
maximum value of 0,114 µSv/h, a considerable amount of attenuation should be implemented.
This amount is quantified in Table 6.2 by means of µx.
Table 6.1: Expected exposure dose rate, at the interior limits of the barrier (indicated by i), for 131I
with initial activity of 7400 MBq or 200 mCi.
Points Γ (µSv m2)/(MBq h) δDi/δT (µSv/h)
Ai@O1 0,060600 448,44
Bi@O1 0,069857 115,13
Ci@O1 0,072746 78,13
Di@O1 0,077954 40,33
Di@O2 0,063345 314,60
Eci@O1 0,081300 26,98
Eoi@O1 0,081300 26,98
Lead (Pb) was the chosen shielding material since it possesses highly desirable properties, such
as high density (ρ = 13,350 g cm-3) and high atomic number (Z = 82). The high density provides
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Table 6.2: Lead-equivalent thickness (mmPb) necessary reinforcement for 131I with initial activity
of 7400 MBq or 200 mCi.
R401 R501
mmPb mmPb mmPb mmPb
Points µx x total (mmPb) existent needed existent needed
A@O1 8,28 25,20 4,04 21,16 2,30 22,90
B@O1 6,92 21,06 5,39 15,67 2,14 18,92
C@O1 6,53 19,88 3,11 16,77
D@O1 5,87 17,87 6,75 11,11 8,15 9,72
D@O2 7,92 24,12 5,26 18,86 9,16 14,96
Ec@O1 5,47 16,64 0,61 16,03
Eo@O1 5,47 16,64 0,85 15,80 1,00 15,65
greater attenuation for a given thickness, while the large Z number increases the probability of an
interaction to occur. The more interactions take place, the greater is the attenuation. The most
probable interactions’ types are present in Section 3.1.2.
The lead thicknesses necessary to provide the desired attenuation are present in Table 6.2.
Although a more close observation indicates that the barriers A, B (mostly in R401) and D (mostly
in R501) already present some amount of shielding material, an overall look indicates that the
adequate reinforcement approximates 2 cmPb (1,65 ± 0,37 cmPb) for all the chosen points.
Lead is effective in shielding gamma radiation, while for β particles a first layer of a material
with smaller Z is more indicated. This double-layered shield aims to attenuate high-energy beta
radiation while minimising bremsstrahlung [2, 44]. In this work, the first layer was not taken into
account since the charged particles emitted during decay of 131I are practically restricted to the
thyroid gland and hence, will hardly reach the shielding walls due to the weak penetrating power.
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Chapter 7
Conclusion
Radioiodine therapy is subjected to strict regulatory control that seeks to provide safety to others
than the patients submitted to the radiotherapy for thyroid cancer treatment. Whenever the patient
is administered with iodine with activity higher than 740 MBq (or 20 mCi), he/she should be kept
in an isolation unit until the radiation exposure dose rate, measured at 1m anterior to the patient’s
neck, drops below 30 µSv/h.
According to D.L. no222/2008, on 17th July 2008 [63], the maximum exposure dose limit for
members of the public is 1 mSv/y, that is, 0,114 µSv/h. Therefore, the walls of the facility should
strongly attenuate the radiation emitted by the radioisotope inside the room, so outside the room
the exposure is always bellow the accepted limit, even for the extreme situations that assume an
initial activity of 200 mCi and an occupancy factor of 1.
The present work allowed to conclude that the current dimensions and materials that constitutes
the unit walls do not efficiently attenuate the emitted γ radiation. This experiment was conducted
for different radioactive sources with different range of energy emission (from 93–723 keV). Thus,
it is proposed a shielding plan that suggests a reinforcement of the walls with at least 2 centimetres
of lead (cmPb) to the already existing materials. The determination was based on the assumption
that, in practice, the exposure rate constant in air is influenced by the distance between the ra-
dioactive source and the absorber material.
Following the proposed solution, the patient will benefit from the radioactive treatment while
in the surrounding areas of the therapeutic room the exposure will be kept as minimal as possible
and legally accepted concerning the dose limit established for members of the public.
As future work, the shielding barriers could be weight, volume and cost optimised. Although
β particles have weak penetration power and probably would not reach the wall when the patient
is placed at bed, a first layer of a material with smaller Z, such as plastic or glass, could also be
added to the shielding barrier. This double-layer would attenuate β particles while minimising
bremsstrahlung, providing an efficient shield in case the patient leans against the wall. The room
design, structure and operational management could also be improved so it gathers the adequate
conditions for the number of treatments to be performed, the flow of patients and decontamination
purposes between patients.
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Appendix A
Decay Schemes
131I decays into 131Xe (Xenon) with a half-life of 8,0233 days by emission of β minus followed
by γ radiation. The primary emissions are electrons with energies between 248 keV and 807 keV,
but 89% is 606 keV, followed by photon emission with energies between 80 keV and 723 keV,
with 81% abundance of 364 keV.
99mTc is a metastable nuclear isomer. This term, denoted by the letter “m” after the mass num-
ber, is an indication that its nucleus stays in an excited state longer than 10−12 seconds [2]. The
nucleus will eventually relax to its ground state by γ emission of 141 keV with a yield of 89%,
which only rearranges the nucleons. 99mTc half-life (t1/2) is 6,0067 hours.
67Ga has a t1/2 of 3,2613 days. It decays into 67Zn (Zinc) by electron capture followed by
gamma emission with energies between 93 keV and 888 keV.
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Figure A.1: Decay scheme of Iodine-131 (131I) [43].
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Figure A.2: Decay scheme of Technetium-99m (99mTc) [43].
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Figure A.3: Decay scheme of Gallium-67 (67Ga) [43].
Appendix B
Weighing Factors
Tissue weighing factor, wT , for different tissues and organs and radiation weighing factor, wR, for
different radiation types according to Directive L 013, OJEU, on 17th January 2014 [4]. wT for
thyroid gland is 0,04. For photons (γ) and electrons (β−) emission, wR equals 1.
Table B.1: Tissue weighing factor, wT , for different tissues and organs (from [4]).
wT Tissue or organ
0,12 Breast, Bone-marrow (red), Colon, Lung, Stomach
0,08 Gonads
0,05 Remainder tissues
0,04 Bladder, Liver, Oesophagus, Thyroid
0,01 Bone surface, Brain, Salivary glands, Skin
Table B.2: Radiation weighing factor, wR, for different radiation types (from [4]).
wR Radiation type
1 Photons, Electrons
2 Protons
5–20 Neutrons
20 Alpha
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Appendix C
Experimental Decay Values
Logarithmic representation of the fundamental decay equation (Equation 1.2), where A(0) repre-
sents the initial activity, at time t = 0, A(t) the measured activity at the time t the values were
registered (shown in the tables) and λ the decay constant, for 99mTc, 67Ga and 131I. The slope
of each graph represents the decay constant. For each radioisotope, the experimental λ is the
average of the decay constants obtained from the measurements performed with the two dose cali-
brators followed by application of appropriate unit conversions. The respective half-life (t1/2) was
obtained after application of Equation 1.3.
Table C.1: Experimental values of 99mTc activity (in mCi) at different times (t), demonstrating
an exponential decay. Activity values shown result from the average values measured with two
different dose calibrators.
t A(t) (mCi)
00:00:00 3,5017
00:33:16 3,2771
01:16:15 3,0207
01:51:54 2,8242
02:31:14 2,6117
02:57:10 2,4899
03:49:51 2,2436
04:39:29 2,0412
05:20:17 1,8865
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Figure C.1: Logarithmic representation of 99mTc measured activity (A(t)) in mCi vs. time (t).
Table C.2: Experimental values of 67Ga activity (in mCi) at different times (t), demonstrating
an exponential decay. Activity values shown result from the average values measured with two
different dose calibrators.
t A(t) (mCi)
0:00:00 0,3325
4:45:00 0,3168
23:37:00 0,2713
28:44:00 0,2561
53:19:00 0,2077
124:49:00 0,1164
196:49:00 0,0593
221:04:00 0,0478
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Figure C.2: Logarithmic representation of 67Ga measured activity (A(t)) in mCi vs. time (t).
Table C.3: Experimental values of 131I activity (in mCi) at different times (t), demonstrating
an exponential decay. Activity values shown result from the average values measured with two
different dose calibrators.
t A(t) (mCi)
0:00:00 0,6651
22:35:00 0,6263
46:33:00 0,5734
71:00:00 0,5283
94:30:00 0,4854
115:05:00 0,4526
166:30:00 0,3787
190:30:00 0,3484
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Figure C.3: Logarithmic representation of 131I measured activity (A(t)) in mCi vs. time (t).
Appendix D
Initial Activities
Initial activities (A(0)) for each radioisotope for the exposure rate constant (ERC) determination
and the unit characterisation.
Table D.1: Initial activity for each radioisotope for ERC determination.
Initial activity A(0)
Radioisotope mCi MBq
99mTc 21,88 809,56
67Ga 8,17 302,29
131I 13,72 507,64
Table D.2: Activity at the start of the measurement for the characterisation experiment.
Initial activity A(0)
Radioisotope mCi MBq
99mTc 59,42 2198,54
67Ga 8,54 315,98
131I 13,87 513,19
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Appendix E
Dosimeter Specifications
The acquisition of the exposure dose rates was performed using a portable dosimeter (Atomtex R©,
model AT1121) able to detect photon radiation from 15 keV to 10 MeV and dose rate from
50 nSv/h to 10 Sv/h. The overall dimensions of AT1121 are 233× 85× 67 mm with a weight
of 0,9 kg. The device detector is made of a scintillation plastic with a diameter of 30 mm and a
length of 15 mm. The portable dosimeter is presented in Figure E.1.
Figure E.1: Portable dosimeter from Atomtex R©, model AT1121.
The dosimeter was set to acquire the dose rate every second, which was automatically shown
in the LCD screen thereof. AT1121 also registered the date and time of each measurement, the
associated error and the maximum dose rate for the time of the experiment. Only values associated
to an error equal or below 5% were considered in the posterior calculations. The intrinsic relative
measurement error is ±15%.
The sensitivity of the dosimeter is influenced by the radiation source position and energy
emission concerning the horizontal plane around the dosimeter, according to Figure E.2. The
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accuracy is maximal when the dosimeter detector is facing the source. No information concerning
anisotropy in the vertical plane was provided by the supplier in the specification sheet [76].
Figure E.2: Standard dosimeter anisotropy for horizontal plane (adapted from [76]).
The dosimeter was manipulated through the PC, by Mediana software from the same supplier.
After each acquisition, the data was stored in the PC in a text document, from which the results
were extracted to be analysed with Excel R©.
Appendix F
Experimental Exposure Rate Constant
Values
Study of the influence of the distance between the dosimeter and the radiation source on the expo-
sure rate constant (ERC or Γ) value for 99mTc,67Ga and 131I.
Figure F.1: Horizontal angular influence at A) 1 m and B) 0m height for 99mTc.
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Figure F.2: Influence of the increasing distance in the ERC value at a) 1 m and b) 0 m for A)
99mTc, B) 67Ga and C) 131I.
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Figure F.3: Influence of the angular displacement in vertical direction when the radioactive source
is placed at a) 1 m and b) 0 m height for A) 99mTc, B) 67Ga and C) 131I.
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Figure F.4: Comparison of ERC measured at 1 m and 0 m height for A) 99mTc, B) 67Ga and C)
131I.
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